var title_f5_23_5488="Diagnosis male infertility II";
var content_f5_23_5488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Approach to diagnosis of male infertility in patients with normal serum hormone concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 541px; background-image: url(data:image/gif;base64,R0lGODlh2wEdAuYAAP///wAAAIiIiERERLu7uwBmMyIiIpmZmd3d3WZmZjMzMxEREe7u7szMzMwAALvWyVVVVYi4oAAz/0SPae/v7z8/PyJ6TvG7u8/Pz3d3d9/f35+fn2ajhU9PTzOFXKqqqt3r5JnCrb+/v19fX9pERA8PDx8fH+eIiLvJ/0Rp/4ig/+BmZszg1i8vLxFwQfjd3VWZd29vb+718X9/f2aF/9MiIo+Pj5mt/3etkvzu7tYzM93k/+uZmSJO/88REa+vrzNc/xFB//XMzKrMu+7x/8zW/91VVeR3d+6qqlV3/6q7/3eS/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADbAR0CAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi0QHl5ufo6err7O3u7/Dx8eP09bgB9o/4+fz9q/v+EgEMSLBgp4EGByFMyLChPlASUEza0UOCCkgoJKha6LCjx0IcFWWkIWjkoYiKUlw0tCQFI5QAImYEoMKlSlIhP+psmBNRRglEANCQQNIQzEhJVio6CmDmoJujeu6cGlCqoYwqiQQBQrKihB5FYkpMIkECkKBPL5ote+NGWQk7/1SUBZvx59sdMjXWdMsWZUa0mqxSHVxPMKGMN3qooJGiqKAeS8SqOAsAiFIANy3S7IH5YpEgYZckybgSZl6aNlfSILn6IOHXBQ0PykhRQpHGRIaWJRlR925CmSUm7gyA71ynYgWdrkm8aRC8O1zDns5Pdkm4zBu7DcpVMmVDwYtzvvk57PVBEpQoRzEze2RBKYAkAVCEqSXr1PNXw0/7KY0dQMzF21hv3QCcWsKNt5JcuyGnG17s6eUSXwYqgRJzgemnYTj4DYMhEBJluOGI3HQYzA5BqOeJiSS2aAyLHLoo434fwTjjjbzY2AlUvuiI44+28PdVUIxtwuMoxr01if+PQDYZi5A9sOaSJkeWUiUkTDqpJStCuoVCkSgEIUEQBqqUgmJeARFgekIV2JwgN4ipGVlmEVGXBF6Kh5lXZ44ZXSFXPrTloMAIucOZRQZxUZxExBedCj3sgNdFRQ5CAxBvYvYeTZRZRhoAEOqZwoQoKQbeZZFkSeiqUUVCW30SpACdcocuOOWFLqkgp4KHBZhCEb4R5VSow93k1JWBOqIqq8yu6CpcbbqkKE1BNGrreqjhpd4SvBqSBA2TAYYcnnsSdyyqxNUXoqDNtjuLoaDG6tyYZV6bXHZzdQvfXGHRiSdyDALB67mnoibJsu4mXAnCxIB4sMIQt8LwNRNHbLH/IhXTePHGONXI8cehZEyNyCBfTDIhb5UFwBJv0WAntEJNaUhr6BlYnEamnFwyxDorZzMASjxHHxA79BczIjT7DCfOpfS8s7tOkytI0Os2BXOlMzsWk81uneL0081G/dZFk415kV1lyVxI0jGlzHTHYMdNSdQ/E/KZEkZjvbbWUneds9yAp3qK1DS5TF8QEf5ZpLqEsN33260GLjkjdM+2pmZ556p2m28htrTXk4cu0C4O3/K16ECezozqqN/IujKvt+5i7MjQLvuI8uSu++689z7P7cCbHvzwCdlO/PE5Iq98PsYv7/y7z0f/TfPSV2+KBhgIsg8GGljv/TMUBFDB/wYBbFBBABR8rz4zI6AzwvrwJ4MBOtnHb38x55dTwf38D0N+ORvonwCBUYIAlGCACOzFDAIwgwQ6MBcaCED3HkjBWoigghjMoAY3yMHp+e6DIAxhOjrIMepJjIQbMyGXUGiy6bHQYir8xwsjFsONzJBnwSDAsmp4w8Ik4gALKMcAGiALHTJCAANQVg8TFhIGBOADAGAABA5QxB0uEWqIcKIACgGBciiAATo0QAAW0MUAZAAACFBAORIAAAEYQIxfJEQCzEHFAagxAGxEgDm+aEQDbJEBC/hABszRACQCYJDlIOIheHjFGCHiAANYIwMEEEcFCECHBACAAZJ4AHxAIP+PCyikARAASCoaIgEKAMAAkqhDBAxCjx8w4gEMAIBZAuCJgzAkLjHWyLAxggEKyMAczZEAI6pyi308xwEMqUlTCkIAQQwALQewRT0ioAGRLMcBjAhIAiiAim7E4ySTGM4EMAARjOylN0JCgCFG0ZKUPKcgjElNABjxk4RgpgGcCctDTrOaAUAAKqMYgG3ug5ILKMQClpnEQSwUnepkVUgQUMYAQEAQFTWoIOppxDSaAwH6dKYqy/HGY6IxoAQIohg1StA/RvOLSASkF+VpiHRGdBs2XURKaTq3mxIqp4oIJiaA6lNrEFUURy3qNJIKCqYqFRpOddZTmxRV6Uz1RyL/zKpWeXfV51W1q3L7KljBJtax7qysZgUZWtNaQrbedK1uhWFc1QnXuSqsrnYN0lb3yte++vWv8sgrJ/A6GMLaz7BTQSz8FKsTxqrPsR6BrPck6xDKVs+yDMGs8rCnPUFw73mcvaVnJyjYSIRvfOU7X/qcd1rymQ99pZ1E+87xvujN1hy1jW0k5neO+j2Pt+bwrW4hkT/xWa+4+xuuJP5XPusxN4DKlUQBD+i96UZ3EgtsoPeye11JRJC01ftudyVxQfWVd7zoTa96ZYSBGBQXsPAFYQViIFyHaMAGHWhBfHXXgg7YALzP+4EJTBADEax2GxQQQQwG/AOHiOB8/j2v/yxEgF/xSRh5FOiACaA7jg2YoAMHDkiGSzCDEN+CAjMoAYiVR4H+mlgcGW7Bi+2hARf/IsYAvl2Lc8uPEcjYHzseho9njLoOdKAgRvZHkomxZOAJmMj1oIAJGpwPEZQgxE6kZRUTQYESXBh1G6aEMa/h4R7HoBAIzWQvYsBj1GHABI7wpheJaERm8qKeljBBfcWh50L4MQFs7ORHUzpGKhL6oUAsxyUDoEYDELGMfAyADjspRjx60Z74EDQeCfFm4MXgzIxAwALYqEoDgFGzg/g08wqhQzAugKYDYOMCtghEQNL61QM44zwD8GgIxBMAltThFm+5xQSMUo8EGHMtA//AU1RzowJfPgQlCRHIOrOy0vjwqBk1ScyRBmAA58wmuBtwx4syWpv2rHQdkejHSivgjlCsZ6UdHYkHr1qOynxnHgOqPWv2W85DNKYbh7nGMUu6jQ2VtCzvyG+FAA+2jEhAQwWxT2sDYAFnvOdFG7AANadUlAwApgDcGHJ4plIhW4Tmxan4gYTa0ZVuRIAei51EPFNc148IXz76LAhAQrGNX7SkQ1P+6lm38dWD+KQxFZCAX+9aIZlkpsLxYYAzfqDhAOj07QwzbYfGEh9I9HcfTTkAKs6SiIB+JqBJLYAEUJTRVDx4K9GBADxLPeo1FwADCE5qLOVjBKCuZUIFMfP/cyQ7iA89dB1J2gAdetGVGTU43rWXbLCTFOtsfrgj9EjqAZja4kYXgCc3LulZurKNpmaAH0mu+mGj/paZzAAtHzoIuyd88tTs5DmZfnSe8tIeVobyJZT9iS5He3KykTOj6Qx2Tl4ejXc84zlqLsRwV1/06DaHATJJgHmbFOGUBz81tW0ANvqaXfVocieI7wn1t25iblyRmj0BSN//3h5BFsaQg7cs7Hdc/rLgbJBQYyvmCzg2PAKYCQmYcx1AYsIXCyimYg8oOQt4CRX4CA8WABFmQRXWAcf3fpjAfktlEPeVX/uVO/31X8vDIsYkgsFgc5SDIxf4Giy4Dy5IDjJI/0I5oWmBFk3hJE06pEah1EaMd0t3ZGiIR0XYxkbiZn3fxgDkVg7mdoTphm7U5Hk/+G7lEG9bNG+KtEg52EFWoXu5NggteHCxxnFElAHmlnKzd2vy9HGsB0+pZ3KEEABEt3IA0HKqpAAwd2x4CAAS9303Nzquo4M/xHAIAHCNZ4P7AGiaJk2wV0uj1HD8dnaCyHZrp3Zv902TOHfnUHfDdnfip3d8Z4gzMoOEkRNVt4dYp3TMhmmCAGhqeIeZZEuh92qm90ypt3q96Hrxd3Cyp4e1N4q3V4q6B2x9V1NhyEE5gX1iVHeMB0xA+IhshH2bdnC2pHi3ZA7U94TeBm7YGP93JMV93md74WdI43dH5YeKMqKKhVU78/c3hyiG8pgK8GhD9lhZzbhB+Sg49eiMHfGPqECQjVUJdvYICVkLMOiOs4OIlLCQjSCRwmCQ9CiQhqBtGSdpBUV4xKRtTMhuPKhHBZeE3LZG4eiE41ZuRohu3WeF7JaF8GZSXgiGAemPhwABG9dxwoZmDYVPooZNfkgIusdMRldr8xRKczhydThyJ6c9efhQfPhyqCdzgTiIMNiKzHiTGgRxhLBPG8VS+dRQ2FZQeHYAimhI/nZLroSJaddGmwiXnRh33BdQdIeOk6iOpththaBzXJlB0GYIOgkADTB1htB1+FSMhXh1IHX/crnIALuIeiHni5MJjLQkjLMnUnh5cHqZjLxXCPb2lxikaoWgkbJYCByHR9oWUHZ3edcURMVkktOXkik5jt0IhFUoiZuJewJAfssoCKSZiiSkdcdwcKXAc8JJQmFWnPMYCmXWjxv0ZAUhZVQmmhnkfvyAnQ+JQvnXD/uHVS/UYgUYZfk1gRpikVORYcvZYR9mnufZQwJGYAbWDQm2YFO2JehJGO31XifYn/EwX3s2I6G1PTm2XndoPa2VWl5poFtZPbdVDm3GoAdqPcBVDgGKOv6ZoRq6obnDD8h1PM4mgPn5XCCaDSLaD9ZVothwovzAXSpKMdqQnwAgXi9qVDHq/w8fCIIreqMSegkDOlrR8KNZV6DLIKSf1aOSkKCv5Z7DoKSqJQ1OuqC0wKFUug4k8qABEKHNgKVauqXukwszKKOcUKEBcKHLQKZmeqb0A6YuRCIfSg1vCqfmkFz30KYjQqLUgKd5ag4cJjzr5CIpWg2BKqgGtAth6iIuWg2JqqgMZKh2OiI0Wg2RKqkS5KiLUJanNzfNeRCbughi6gk5+gyhKqrJc6kipQvGiX5IWhWMAJaE14oZ8EUEV0eV5nlj5EpTJ4REBI1fiHpBFEdNGIUWRXCZGoOrGhutGoqiBgGjJEeptErLlkl+BHuYpEoJUItsmE+/uJRdF36CpmX3N/8O+1mluwOgmFCC+kWu6JCCROqj+JWu6moO7GpVieCqg9BJPwdNJGVS9LRFhpmJkQiu4Getb9l2czmJfjcO8VlgTPoK9clglJCBG0gLFNYBFrYJEmsDo5oKFXuxIqII9opGZASIUDSMHLUP9fSvtDiEh5lEorZMv5hLl/lzqkqfGtanwuBh49kII1ZiuxCBOzsJPduwqwC0RAtRlxqK0woBX5RNJXWyG+WvlTeL18iXz2QOF1WbdCSI5VCsnhoO4nm0thBj7kmAYssKB0gJZntj+dWuNUsLFDlY4NCdyfCdikC3v2C3kIC3vqC3S6ILcbsJqqidx0C4hGC4AtGpknD/g42AuInguP+guIUAuV/7p94gnVcrhUeUd1ELgfeZCMGnCNkkUv96MHVZCA15t15Wb1e2CC0nT3rUq6zmI6mquhvrkDzaDev5eggwrY2QurDwnIgAeIzQkLVruqdZCZkHCcTLCLTXrSEjuYWwvD0FCsBbCxdInLyIUbFZaIdESEikaZAkAED0TKkEaTyFSLzmRr96TuiLRKJHaWNURjgnCMhpCPeLCPW0mlNrmkEoTUTkhbN6bkNYT9gou4WgvY2Qv4iQAWRJvt0GvwWVbSzZhESYSLw6ieiLCAoMkIqAbJIAvMZ5vJZwveGqDcG5vRwHRHC4S6UYtaW0cr8mdApB/7Ost3qVxJR1Ka3ON72B16Ciu0UQcHsaR5g8yWsAMJiD0Ipyh4YhWZjSO6FvewiF6Wo0VZTbJ4tDLLMlJwBQLAjYam4EMMOuB8QPY71lDHXQ0w2BmU8faYkgJUbmpJedi0QfQEsEt2kyK07MFGt53HQN1a/JKwihaZOLIG+mZJiuWnYCZ2qn2MRUe0y2pEQJ2wiWlHZo+VHMNHaDULAJMMnLpn2w98e4W8lmqG4kSQAkyWjuWw4LZY00yXjEiobV978sO4tkaVCTlrJU+JIdCRLrZGLxN3S951AMpUq6tr/SlHJxlAgLpZbP3MwDK8jE55eHwMCGUE+DCcVFzM37wP90nslGuGRMaUdNX8wIHbwI2CxtBvB/rciYm+xJE3fDXmyctQh1TpcI6VyzUjl4qQpLMScInRTJWSl9aiZpS1mtsSZHudyTJhWI8dfPZmyihymwiidTrGxIgja+s4h0Sby1PfdSk4S1GEVH8dy57JcTzZsIo9sAcGSY/rtHMseObDRMA52JJnXAikC9jrDSi5BlmRuNJ61tF2XBB4yN4pxJGYUIPH3Gr0R3sIdNdPSWy0bQe4mSI0wAnkzOyziIzTRmKXuLlRiKwNwNMRS41XsIocsJjMsJxse6ZwuBq7swhkB7UDdQTgSzp9dKaRSS4XxLP4fQv8jV2mpPCwXWUkv/icRoyDhVC2j9t497ZGzdM5RrCJV9C5eNtITgy1qmcCrVkdnkcmPEe+tIUjXdtbT8hIT9SnB02AAR1orN2RO9oyPIZS3Qpbvgt47At72g2x6cCIWJwLBjudIgFWtrgG1bCcfdC2l7H0k7cc5wgSdjwiARxZB9tw3os7pgtJcwtD+bYkGb1iVC3JrATHTcCKWrgI6Qsbd7Ch3rgRgLYRrLgRYL3x873mbdCQtJ3bYoVY6ArvF6DvPqCQAe4OUw4IL7qDHasLPah2u0yoDs4JtmmvzbUXfUg4qWc7TzqStE3trQxpEwUNDaSuZdc6TXANvccVtMrZ4ESthUv+tNpzLE/yyH2g0pfETR9E8nBVINdd4FtcizlMhTW5bbpEbu5Ag3jo9hY+BU6g37fAj9ZLIA1ZjPxLmMuc2ShuVTm5hc9JuKsM4XaT0cbgq7e8gkpePWlJoRnk2BaJoufW79q4hOK9yHILwdPlmDgrnMQJ2vMOYwOiiZ7QuB/gl+bqODwtvF4NtK/j2FXgphiwxk+ySPxSrqibPBoLNxTa+X1SwLO5/MrWAQu8Z43i7jyuTuYK7YO+nKE6JYZequrg76werQSRCN/tsaY539UOumfOvJWTyxTtGzzqr5Ieu4Xh2wYaRuewzI/o48ARtRmuk/Kz6u9aQbsuz8YO1TwaXToO0j8v/s/eDtVIGm0yDuV/ql/sDtgxGn0qDuG0Lu/eDuVKGn0iDvI8LuHjqn0zGo06Dvd8qnBUHvVLGo0yDwJMLvKFqo0zGp06DwJELw/eDwVNHeyiDxhMHw/WDxxzoNFA8OG5/xHn+Hr65VIBHyffXxCQ5VZT0ywfAD7kXy+hMD1dkKGjADFWACLl8OJlABKjilOCjFtd0LHiaf0C4KD1vm7l0BJTACG5CmsoABGzACJQDisOBYCIFZRKUBNR/zvSBgFZDsnTBiNjD0qkABNiCBko7yPl/cvIABJfDDwRADJcD0m7DcTZrcfd7zDsfrt8D2ln7pcU8KUobbwTACJiD2zo3/9nk/CY/N87rQAm5PDDHQAqRQAYKvfzI+489Q9aUZSBiVtdIG3ZaKCzMg+crQAtoFCjZQ+HtuAjbgClSf8lzccl47lr+QTm898a0LCnPNDFbm+pmgvuYUgLBfe8aWxr7MlHB0apOGfQpARLb6bWK0AK7UhAwQ2obtvc9vq9J/wfQ2/LSwAaTPCm0tCS3Q95kA/tBQ/id0CbJPmEN59olPCHoE+hdnmaTk2lsU3IJYc84HCAQABgICBgwMCgIEAQwAjwsCAAcLDAMDkwGChA0LDQAZEI+jAAGkp6ipqqusqh02pA0KAQEKB624uYy5qwKYpDYdvMOjI7CPsrS2xMzN/7qmwCPO06jQ1AAfC4Kjhgu1jhDKDIyMBwEGtAnK16PWj+6kA5KkCAEI3L8GB7uTBo8E/uQB4CcvQYJHAg5mCBCp3r1SCAQSFGCO1rlq7DKyMiGClIIMCA9qZMVvmq9TIlqMRNWi46OPIVfKXFXyUcqZxOCZnBUJgCFEhAQocKSI0bwAkhIYQFBv2zV4Oh8JPNUTYb590BoE+AQBk0Ro8n4yIDRKK4KeAip9lSqg0ydVUXFOg6fgV7tZAW4BpHVL3gBC6Grh/UDP4lBGsww0sERrwcDAffEmqJeOVNyM7uqeqsX3cWe/gJUNJoX43Ke8BhLszQvKYgMEkn0aQDc0sP+/dnJ5XXbW6cNJAAMMWgyg2pomn7+Os4Oqaippb0h/6yspQNmntcAlDaA1YJzFgwS8LegraaLP7xhzYz7VQF2AAaclpQUwHpvjAQruGWKKFEACu4V9wAhXEDDiCCS3ZAMcJowg8JtlubnTHnfx+eRYfQrip99S9SQF4IAAQCBKAKLQl6BjARD2CAQHndXAfgyMV9M76uGyGy8JOdIJASeddYBQBw5knCC/KffUZjUmycyNSrJyWQIKlCJIg8PZM1WRRALYwHZ88WNIaw1VGZEkDj2Im1xxQSmlkJRZNKZV72RJGjRfHtcmLQ6ik8BYw/141YylNAlXRgTg1V91tJT/GE6XQyIX53oQCirpoJMS05JHt/iHyXEZ+FPfKFcmJ+coajKQFz8KiASAWZ+yBUCZUZJyk1yXvpTpf2t2amI882Dp6CioHqRcq6SMxyIp0mEVJACzVkojTmY6++yZ0lbKZLUAGEPKQsrcY5EBU9qWHZxrmhneOacahgAjla0WEJn2dELcKDZII5e2j3Bbi7e0gOvZRaE+aq66a/57CHRDweZmsolc9Ei92F7bTLTSMoftpBJLu4FKTjp18TAtbJDbxh2vBKh6IUf8cY0WJ2kkPpJm7CwFJbgEl8crtyJCCRSoV/MqL7Nzslw7XyxzzjkhqRvOwwT96ylTObcc0qrM/8Ax1de0MEONNpjQM9bsUGDCMdUeDXYrLbPMNMXjzmR2pS3EcLYzMVytXgX2zu3MCBV8bPbQQ2t0ktRAK81NYAqMdtyiKB6Q2rn1KUyLIIsOddJqB1SUl0CIKnAaXrdQQss86ekNAAYliGx6LhuUgIGSYue9ei4jeO13M4E3STil1CLEYX+4arJfOyX2RAkDXcUJJACKnIThffPIo9UnwcsXEEhOzn56CXJrr0oMrguqQQsdfO19KhR00IIGK+vkHmu4DuJ4v8Bx551sotFC2F/cobMAf4JwHHBi4wvNmWNKjTDctMh1nJNowiCWEYRD3oEAfcTpfcTxxZ2sFD2K3P8GIGsSYKHe85bSrU4DFTDBD843ih+YoALsk1T6SmAD87GQAjYoQfly9qQoxW86dDpEIhZhiv10SFMLysQmBNCUfiSxQYObBwQhqMBAIUtUjhLeUtqxDbRUQkSrEt5QYEasAWBPelsJ0aYCeJsVqaqKq9uACUwQAxHYEGwUEEEM5qg6Z4mgAiUYwQZeNzsMbGAEJaiAzdqHirTQ74dYeQQVE7ILX0VRSGxpogAFUiavzCM8E6wiPCy5xvoxpGCQu0UDaLM4i/jJYJnYnHysE8KA9KuEcJzdD2JQgSr58pfADKYwh2mRCsRghR/TgA1SSMxmOvOZvnyhDWJINXjUgzD/uvpSeJQlG6AQ8VcN9CQmx8Wav4yrk8DB3gBLJEoWTs2daIInD+VJDZ1waTavos14GmbL99yPlOMyT+fe9Sp7nKQiCXKaFXtHz6Y1VCZve+hIIkpPiiKNbQtdoERttFGNWLSjcwGpbiR6FhWZMKMi5V1Km/HRlTrUpYWDqUZbej6abtSmMo1pTnMp0rTtFKU/1WlQITpUhq7UpzvFKTw1QEhoYICaRW0GU5/11KAqFWxQgaZWt8pVrUYVFRQIQAU2EIAN9PKOX+VFWMda1rNaNamMTOvKRlAl2cl1GHQdjl1l2tW++rWrcb0rtjBQJUIKdhiEHY5hD8vYlVy1scPo/yUt+gZZXkhWrJXN7Ds1Kyiy0qKPnFWFZ8sa2tK+1LRJKkEASoDaVaiWta2NbSoeK9tRzCAAW6stKW6bW92idqpWrKpvNaKBAEBVt8U97nA1u1aymjUAaF2uMxY5XOpKV7N5tcher8vd7nqXFIm1yGK/S97yLveylK3sX9fL3mGiqb3wjS9tzZuR0YK2sfOdJ07yG1j6Yu21nOXv7fYLV/+CjbcBLrDbFGxgpCU3wTmlrYCN1mCwWRe/DHZshivM4SNFOJ6z210uJtzh7kblA/OSqIRzgah9pULEGoEx2kocIflW6a2ouEQlVAziVnyJeerkVW5knD0aEzhCOC7MKv9vwZhT6qsBmGsNLRoguv6M4smSO4gh8peif92CM6zh6WZZ8aWxlAcyBgSN5EAiOU2QIy+GAYdFZmmaERv5yD3+8CmE4igDtcOkzyuFSc04W5Mey0VGBB4mAn2oNhrVoyxGz64yFL38hEgUO4JArNxs5Udcc3jS8wQo2FnkO2sYyT/VSWDwBCbrEUcrw8kTccYxC/ggS098ciUpN6hJR2t0oiz2h5p4HbV5WBA4jssUp5HBpbxQUR6ac9iMTX3qPPP1FH5OZ1nsMYrxEKvbmQrRG8F9LJiVa9HhruVJgY2LH6dqV6A64zzAqBUC0HvZ/omSqX4kRE6I+rTUhpS1YQr/jwSwkxLsmjXCxmGbGInjniV0+Dfa7CAsXk5cxxGgmD3s49tUcBHiQuhU1rwqdKCDAPw4FzoO0LAFkKXF41ZpwDmOZz1fu+aSMovLZg7pUxTg5yAAQAR+XgAYgIAFHvi5B0IAAKIHPVIbTumKJZVw0qmHxAaOSgEeAAAcWIAFAADBBB7gARw8IgIceMTW1+1SrFds4FLnucBJsXYXDOEUHpgAKta+cZC63VlTv7nc65mKtRfg6aNgAQd+PgGwN53rfe8oRdnFNKQFvkm5W/DgCb93rruA6arggAfUDnmo27wZimAGkTXPembEjxgn+w1GWbp5zvuc617nutjJDnoO/+j98Ww/KjW0oXqr7xznSYo9gNhde9r7HOgAWPzPOQACHBDdA0F3euRvOg33EEIecJaklufsylRKeStZtj1Rc1E5BqgDE+/TS2AS8idTaG4y37mceCJTGTs33/lwJ3xzQST+Yg7iV2+gMg/GUwld5kav8m8AuH4+NkapZyZqUhVIJD81YQ4MIHuLJgnHcwls4n//lzSoFnVL8ysG6B8JoHGuEkoGhWurFmYRWG2sgEFahgmOdA6hlIFANAmGUnFWAYNv0oOlVoIjdYKntySj0iCwkQAIKBXY40VBYiwxV4PMR2ZjhA/XBAqeQjraJCOmYAAggWIOEivOIx9qAS8PMf9tSJiEARh3A/g027EA79ZiVNYl+ydxCROEIYV8qrAorDE4/eIP54IUFVQLYnge6IIA8pIA+scQ5FFQbXiEb+iGgCiAgieBzABGq/N35pVfoAh4KDhmvGAOxPeJlwiHmSiHm2iDbbeKI2Zjw5FkBBeHkieLRjaKMYOL3KeLJcaLgnJ5sQiMHUaLyAhY+5WMzPhMxviMrAiN0jiNMkeN1kiNwniN2nhd2biN3qhb3fiN4oha4TiO5qhZ5XiO6shY6biO7phW7fiO8miL81iP79CM+JiP+riPN2aPvhWPgweQ/mg6AslzBTmQZ3OQAaeQCFlNDYmJD1laOkECDnACAPD/Ag5wAc6QkQBwAQ7wjBPpACJpka1AAhbJkQCAkhHJY6dAAjXgAC+AkRrZDCoJkqhAAivQkQ4gBLxQkytJT8DlVDGEkyRAAjIJAEYgkjqQA0gpkhUJAC/pADUgBCvglDzwkTVgkTngA0jwAjogkjk5c0H5CMKFk4/gAzxwAkopBDlAkQ7gAwBgklUpkjK5AkbwCCRwBF4Jlj85N83VVtCFlyvgkWp5ASewlACgAydwAj7wAnFJko9QA0eQkhrpkQBwAjVwmZlpBDn5Aj7AkwH3l8/1NWZ5lUKwkwCwAiTgkUyJlyc5kxnpkS9wmi/AmRf5mX15NtlFC3ljlkmZkXMJ/5YrEJYmmQPBmZMcaZlbeQE6wANQ6ZQO4Jwzt5sB0JtWyQOZ2ZGZeQRvaZEmSZmPwJEmeQQ5GZUiKZ25STXhRQuGZZYYmZGH2ZqamQM5kJVXyZQ6gJxIoJOPsAI14ANMaZubt54B0J5hCQCnyZNGQAKjQJvf6QD7CZ484AM+oJECmp5zg16kYJapyZG/GZ058JVSeQJ7KZU5OZdX+QgYSZIlCpNyp6GjwKGPoJYOoANC4JF8+Z1zeZRQyaAXKaIuiqFUY1/TUJ/oqY1EKqSMBWA0KZI++o1MqqSHhWAYSqVSKlgPhqFZeqWCdWE/6aVcGqZiOqZkWqbOwI9o2kxSl/+mbNqmv+SODHl8fjdzcbpcdXp1rmhqd/qPh7Wn0biLcNqneXpnflpbhdp6v0hthxpbOKVQSbJ61fhQACkQjsqS6vg2D2JB+CYokDpbg2pKk+N2lFp5JrF8jfQLnXqmgToxdqGpKPd3qbp9NZVjV6g7klCpcjF7sDiOmNqqX+YuvlAdbTIUyUAijOg5vTZA/SeIxvenkkqrwFJEs/ENjKgYt0Ybckat7Rcic7Ym2zoKtrEYXHIfBORJf3F/bfIfdOY5yppi3EBLqDFui9pavQquv+ol/jIKnxYrYUQ9A5CsIghFWxSrppeooGIRA1BJSxEjB+AWo3ZrCMCwy9M8FFj/CAN7qzxSsalAhtkGHJi2FYNjaaPAgb+BRv76RNyGDGkUPKT2aN9Yr5BAGPj2G1viSggQDragcQABsGz4bM1KgrkINapSSVcRbY6WLDiYtCIxqjg4Cu6HHgvRE1ORF5cEhAuDqh70DwTVgzrrDwo1r+ToDCgWQNzGaY7wG6VCg4YwPWpUCn2xtTHoTaraU9D6D0V0FQ57qo+gD8uDEFvYTWYmJX1LChzIPKpiFgJhhlVLhthgULFism3LSSnbr237tavaDNzyKZrAT7+hclTrSsf6CQN1TvbQcmSBhc8qtNH6KxYEc1e0t7cgiLHrSqaLsdzaGZ6GF4+DHs0mH+JU/63x4g3qGrqkW4mdcxqVB7ampbxzZ7AiRbC9uI7Ma4qWmlLQO4yXK1fTK6v0tb3oKKh0u5DZy6k/ew266qnh+6jlmxuJuL7UcL2/Jo6NSqpQ474+ZqrnG3wVZauvqx4ZsHyd6oE5Zr9CZY6jCL9kZqoQWb3qgcDTAAHGF8AKnIB/eKmogGWxwT/v4T/e8qo8QT2gKzVkESMCAhnn9yIMMn8XxxdN5hjcqz2XYX74URnpZwjYGg/lOhD7164HUWX0J4XPIYma8xAGFGVPln866Bqcc0stXMC8Wg2G1iKeIIIHNAgYSw7A8UZqIjVf8iWMZlJpSEYn0rEvPDuXsYCW8P+xDXBongAjZaTGYRyCakxonmYPRojGhDMVX2xuvhCF2eGwoUDG6GvBeyaDfYIdo8oPELSDBOW02mALvLZle6JBk0vJsRa1zeq9LkuEUzs/unYVQua2lPwQHPQO+1Br1yEAGfBGnBzB8BJrktyBv1BAjgZtw+EPmOzE8rsKVihk5oFvBtGFukI4SrFj34YgYQwnx6xzBcvAxaKGliAJZlhu5HJsrqK4H2gh0dy4bXgsAAGBkADNeTyF6QZufIYcfhxquKSyldjMu0wKfMgAFIfIVwwNEHRPjayvVuYu8RyJ0ZHC/ZJwMafJ8fsPO9y7rxKEyRIP3RqJ9YHQEPcSpir/w8aHUPy8cI94Eni4xOkg0Lr8suA7p7zgwCPtvjFCv2Y8vl9F0EC1CiSdC0SWAfwqTyyNYYLF0jWd0tIb0kGrqCodVThNpz9dVEEtvjt9059KYzndp27a1LSwpk4d1fxopksipUtN1ZH6k1eN1fobkVvN1e6s1WBNj7n51WPd0mJ91ktY1mq91n1p1mMN17Il11xN1/Ta1jUm1U19V3rd1760knb90anGqIANWYHtspl12Oxo2HxN2Ljgk3JhmcdIDJLdDJWNNW532SojKN/JQlGRA1I5CpCNE5qddagQnDoAmxdQ2pf5pKrA2v2Fl0/JoxkB29ZyCh5ZA0ypmivR/9mzigqHWaHhOZM1YtvlpRPD2Z+o+QisfQKunQrGvdkb+pIxOdrOEN3YSwq5faLPfQ2+7T1RkZXJnZIi6pwkIKLE6aQ54JEeeZVROZc6cJFOuZTYLV1jeToxNN5IOZmx+ZFXCZbv6QArUKI5eQHmqZ4j8DqmgAEJLphFeZRuSQLrnZHRKZVgqZTyrZQTji33XVXtDZwMegE+8Jbm7dxZGZU6IKL7GZwlrj0MruCn0+A6ud4AmpIWyZhxGeIwiZn0qZiEGZ4W6Z/VTdwYiQT1vVyi6VapeaDOTZmXfZ9NjpSd+Zk+YJFHLigmIFZabgIxOpgVCZ+6HaIn8OM2npo1MP/ko1DkV44TSR6YsumSvF3lADChbakDjomZ1R3krr0C8f3dppPlvdRLXK7cVgmeb26RGPkC430CXi7aGhnlGSkEbhmda+5b1Jk3+m0E/L3a/g2kLxDl5lnhjlnpSWIDVUI2vimSF7DojT7crT3ckm6VpC4Tl87cMHmaDmCUQQqTnQ3pj86gjCmSmennemPqw3EMWxmhhwmeRzDsiL7jYZ6Vlc2Rvs7nAADaPDDrskWghjXeVemY/Q2Vk4kEOx7fUk4Kcq6WWEMzFsEzXZ7hhhntY/6Rrl7t8Y3t2j4S3G7rjlmVDJruANrrPkrtur6fzf6Y3sPutODucw6XKrqTTln/Axr5nYkel+o97b8+3CJu4dlO7w0Go4Reo6AZ7jRK3UIw4gPu6f/9lWCTXbLDoVU58Rfv8QSv8SP+kh3/MSAvm/Id4iOOlgj/6uDZ5G5ZA85+Pi6PkEkqV8VFC8qVU0uvWU1vXA0ZpXcV6Gll9ZyF9Q1ppXflXGnl9ZwF9g25pYKVXlFl9qGF9ggJpml/V24PWU+P13Rf93Z/936d99A0W3qfjJbR92j694A/+E+tJIoNiHbtDoevQIvfvEpoYoNsi43fO5NPc3hKXlGR+GG90ps/101S+T1Xxqlb0JyP2J5v+Mcd+YNt+kTd+Y4tp96V+UDt+kOl+JCP+iujq5kn/920Pze7z/ilujrti4mgX8Eswwqz0M5Ng9L9qwq5c73KgauWSPqqgDwWEWQQ9arOfzS2jwsjVAuiO8GPAnvQ8Pus8L9AK5CjSpCfTxN2SMAZofu7Af3MD7SsjwqJ4wiFUiOAAwgBAIOEhYaDgoSJh4UICwmDAwYMAgOMigSXmgSLmp6GEAKfiIWdjA0DAaoJDKOungOiAZmvtbO1nqa4uLqECRAHBoMEBqoCCAqqsweJCZCznJwHAqoGDQDUqpaFqQEDDJzJ1gzdC8yqB7GSCdsGBwAQqo/KCLfd3+EBC9eMvb2aDQK0KpRNwbUByQJAQqYsU7wACsBB1HdtVrEABv/qqYrIaVenfwQVFFrwQYCBBRAZNEgIIQG9AMESGBBVDwHDABAuGuhIAKU5bAaKRSzUU9+BcwEQfProicECCMMUKN21KxaAW1SX0spaiqvHS04/OM20QNQgCNuWNXtGgJOoBvsAZIAQMFMlgpMYKBDA6RoECJwGArA6WCoAdoPcmZx6ldYskwz08rUHqZ/lWsQMBbyGeIAlTgggiGwsYOjeaIPZdmwU4MNqW10/ISakOO/M0qUcQwUwE0BNtIRWdywL4MACShmdviNE3Dg5s0tjXzJ56CakStSYFXuqKoOhbAEaEEM3WNbWw8reqZsZK+nDiCtVtaQX3Oc77Ek1gfT/evkQUoU10bacWoM409hq/7kjDDbbFFiZAAmsRl0G+ohCGGGzuWMgJogQsCGEq214iD+4BMRYcQtmZlVN7nTokjIRrnVgIqik99orTH2CG3MlbTNAAqFB9A5WWPXG4nIACJdUflchcBdvSAbYJGHRKeLJbPS05Ns+JmWCmgGWMFNIXcy988EC5TXGSAIiIaRUl9iYJsCOHRrS3HFw5sIfbIwM4F2SAhF3FlR1gYaMajTGNchm8DQIVGQzraZAZQCY6GckZlHX0zQZKfJBh5AxEKmM/Un3igKGEWBQeI2m+Ruhjw01jIzQCHSYSAzAdKMrOXpST2WSUGKJI0hS11qd/6lh416DgQEKAHEC4NkOks+KEu1zvJp6CHWDsKgMTE+uZtWNwRCiET1WYTVItNWkyWCB3wIZjwJDnidlUk/quWe21bGaGF8oBSBAA8UUk0kqC0w6IyHgQfKiAo4Opo1EGyHAySrFoUMYAkL9VA56Sx48cYiUGkIiLgiU411BB9GUFMEY3fKQrrQSoBdGRRVzwK6j9OqJqhtdAx5U4L3zYj20XJyMTSzdvJMgRf30ZIv1GeVulaRo4sg3lbpXcriJjNsJmYP8REi6W9XzaQbCEPZkaYIxLMyxI1krbc/78sufunn37TfeI/79iYmC85l14Ygn7vMp3SjEwE34biOuKP+7gieeTmny3U1Q7uY78zTpgcxY1PdFXGriV+3LN+qs73064hcL3Lq+h89ue1aL36476vv53fvuwPv+evC350788bX/jvzygLeuPPPQY61t9IpPT73uxl+vvcm2P8/Ixeftufq6qmxfu5U6mm47+HlnjyxXVJqfvPz0W1+494fsJfj4uYaPer56sx9B1Dc7/fXNfWr6RPy4AZ1d8Gxv/ksd+t5VP+3hzysXHEkEIXiIgOgOgM0TIMMI2LoFbBB3IhzfIRZ4tgbi4oEYjGCvQCg/FipugxlE4StY9qIF+YZVfVEGfFjSiITIbCOiWsV4YFIeSVgHKEJRCREJgRQgwQj/R6+rIlBQMkT5KAsjFUnIO5Z4jISU7IsG6SEV0RSnc3URJ4GboLmMSAAxHeY6yijai5gYP+MYYzZ+ig9OMPceiWznIX+iTTUasMcTSfBwNDSfDYGXQ6o8j1GIWd2P4EEptdGpEMAhjZxW85MzFUYpWnJEAxajnE/6RyCR1M/wBsEM5EBqTqOpVFzmchVrCUNQnNwSP7rGGUvwTTnPilJrXGkqXYSSQHck29UK1KYGXqpbSakJnSQ0yluAKWOXMIB3VDjDoKQEkBnIhzXQ2AByyKMwGHviekyykYR8ao9HsZF9knQRQTzRJFH8ojUECZVZEFSOvHtFufiZwPrUpEbo/wgSvQpBtVnsUSEdOZcqUmaWfoJrWhKl1gGM6CQSDk8XI6XHk34U0gSpKRhS4s23kLTQzKyuEh8QBkRhEtI4ng9KHbKjMxaKqXUFrG0NBNoAWpaBhcxrZ82I1+ScRQgG7JEtpVoEK81Rk5r0BR50YRU7mhUJWDUglftwE1BsIrvZUNNdd3KKdzqC1lUmxxxwucZcPhkrn7LukqwCzviCYgk2ASBXxfIhWLtGALgFJxFmK2owR5iYxFLUOx/AVy4DiFDeYDZyW0psXnODomoRQksdDKwxw1eP3hgWsXLzqzNh1ZZsTkqal1KbXJDKCC0RQ1HrelorHDuropLLVgqjG//3Jjg19QigqVQ1SU2FQSHiEAYmHk1HptJiF0uwCyOuYtKSlNKR7DY3QT2dRU9/ijjvsayhVLxFzsAVOkLALBkOsVEilshb35C0uUUjSDVehpIzytKv5IuZk5RBtNA17KXCKIrAIHei944vAcdJEkp0FuDl/vS+9tCHwix3jnRUo7+RWOQgIJZgmDgNHvo1biduYgCHbdTDj2wuP+MiqQQwKpRd4ygAMhuakrmNuwzSLdsG8ydoHQdagkDtuqY12u/MbSvceuRfK8hl9layy7Jd3liWN8NprVhyQnxT0GIHicbRhKRHrtNdNieMEpMuYzHzr0rN3LAAP6a+Wk4omOv/d7JBu66zu8vAZomHwDFT9RWTbF2Wqze7LxvaebO8NBYRrWnxiVDRj8VFpBGXDRNiutKd3l6hU80LEbL6K5x+dfG6h7pR78vW+jmhJmi4aq9EkmOyYx4CBfdAGNI61rJGtbJ9pUIFuvB9/ME1r3U9HdP1miuRzIBJdzds/gCwI9++IK43zd5kH/vUiLNhs6vy7G1Zm9qM4HWmcRHJUFCv234rtqU9jWxzCxrdwbnIATRCADe24iELQFppraITRqo0aFcJRiq8ZKvT5lHh5SLjFTlUyF9EIgP/tPa8RwGezwgcKUFKSTToC8ariFEuyhimJV3tKzPCUyHvWqIg7qJz/96IIiz0hIg9y+NOfWCQ5v6+37nLNGQ2qsuTnfphJsoVP3GqCZPG3I2BRLTW8mD8l9CZtmNP8zKvCVPeCC7RLe5SSjRZZeyTecsuC+rLq3yK3+V2RV0HYFa2U27nliBOR8pVrsXUQxSdmUzcdJj3pFMa4D/8llIM2rgDiOjrRL8qhIdx5WEknEkOwtTXYzrti7b5uZAwr8jTXouFVkKjSbGK6RH0rc4XvhisOHq/PZHd605jAAECN/Dz05GxTPRJa7eEVarbbnIH2vGQfzzTc/NacEU94oNBai0BkNxP/Xi1Z1PAbuR2S+xLwrTrWrQo42YcU0uZgtb78veTycA4Cf9mNVWuE1HpzxV8X+L9VkFkfqcs7wJl6cdGyNddV0M4jHcV3/KAEBiBEjiBFFiBFniBGJiB5bNsAdcuB7JhfPROBYFUNGZj+AJx6pJZ4XMzC9AbI6hhxgAXOMdx9fVNerZRaIdjVPEwJtcuhPE5r/FgtxAMToFEutd4n0BhbvYu55AMTLgRiZAr2yVnyjcZGNN/XbZvSfc7jAI8sWRBI+d4/ucK4/YzGYY9WQh9RxhO3hA8jnB3FXRtaihHWthCe6IAiTRrXFaH5saHc2g4SOdvY/iHz2c+fihrh0iI0rN7WxiIipiI7aWIrSaJHMiIguiIhAiJSkeJnMWJm6iDj4j/iX+oifvjiSFkiqXIeqMoinNIin/jipemgbI4i7RYi7ZIgf1wi7q4i7NYCrz4i8DYi3uIisRYjJ0oibB4ica4jMxoiY3YjMcIjdIYiqiYjH04jdjIidYIhtl4CdvYjeBIScT4ja9GjuF4jtGHjOjIiuvYjvfGiRqAAVmDARrQjfE4j/XojvooPxjQASKQOiLQAfL4hxQQABWwAQGwARUQABTQjQV5kAm5kA25jxSpPSYQABeZkZI4Ag84AuHIkd/ikRU5ktGDkN+yAZKIAQ84kN2okt/CkiQZk8RDASWgDCUwkYq4kKpQAeiokwYpk0B5PDGgDDHAiSaZkOh4lCgZ/5RMqTsaoAz5SIk1WQLtOJVNeZW3s5A86YkzEAAz0I5d+ZVYOZao8wMB8AOm+JRReY5qSZZuiThbaYr/6I5z+ZZ2eZd4mZd6uZd82Zd/FYyAGZiCOZgT6JeGCT3m2JRaSJiM2ZjKcJjXk5hMuZjoKJmQ6Y2XuYZYeI6WmZmg6JnROInh2JmgiYSlqYqiCY6kWZqrSZKUyZmneTytOZKv6RUPUAAF8ADUc5uqE5uMBn0RMAGXFgG4GZqA+ArEWQAcAAAeEAHBE5yDAJ2EwJt455toOAq3uZwAkJ0AMAHOaTvU6QnSyRXe+QnlCQC5yR8ykJ7G6Xy1IJ0uoJvAM56GEP+emmmdlXgJt1kAMgAAHKCc8kOfiHOe+8ICBXCcDfiewvmfBWABhCADE4CbLtCdHoCbywkCFQqgwUmcIdCgBeACMICbOAAAHWqhIICbygmdD2ABKEqiLoCb35ma+JmfjHCb3ikDLuABy1meyVkALOCdE2ABGCqiLgqjHToIHLCjwSmkGZqbvLmiRoqiy0mfJ4qbHiADLJChMICeGRoC3emcBRACFpCkKBoCJRqm6RmhBTAB/VkAXWoIasqmLAqgp5igyCmc6Cmfg3Cb/TkIE7ClBsoCMHChLsACEWABunmbumkBwnmkhNChMiCd0OkCzsmbEzCimzmjS6cJtymmEcD/AROgpAaqpxPgASAAADAAqPF5qY96oP65o6aKqh4wCE56oJR6CJAqoINwokMQAbNKCAXgnBEwoeVZAFtaCBwwq+eZm4cqAzLQnOgprA5KCM36rBFgn4top64gnexJCDjwoc65rGKKomEqndRZnrwZAk0KApI6ASd6qk9aoRPAAjOnqZuqnwUAAiz6o0oqpoVwnhbgpd0ZAg8gryzgqEn6pYMQsLT6ALf5ro+6rvT5o2UKAiHqAV6ang9brPI5rLjpoMv6AAkLAJ+apyQ6rUiqnZ+KrbRzn9uKp91aCAYKAuU5BPk6qIVgrq6KrgdqASNqs+z6q5MqrK46CDgLa/aa/46H8LDQGapfOqqEcJ6pCgBQa7Qc8LAYqqRGC6i1CgC3urA/m6/0mawAsJ4CS7IOmp44ALJgqpu8CgBr252YyqwW4KwW0LYnm7N1KwN3y7IHdmi4kJzLGbP7CaBqGqwAMKS4ya54eq6VeqDJyaIgwAIvygHQWaIV2p0fS69Im7T/5gkPG7Va26M/+p2KO6JqagH0GqE5qrVUy6Is6rAH+gAvGqyRK7Z4uqcvyqIh0KMZ+7G6ybF++rEOWqIdGry4yaYm66//mrwy4LeYWZ0DGqOGNpuZab2eMLOJE7Nx2JusQ6DV67lKCz2FS72Cw72E5r2jKb5bxr7s+JnTiL2QKf+/+libqum+0pc3ukqyucsV6Bs9/5uKgBs8LAu+S1u0oOuq0Pu3+PuKewK+TUu9+4sLAcw8MYuip9qjMDC5GYqx6Lm4LZupBIzAr7DAhWDC2drA6ts3+zvBtVDBy8O9aqu6iTsBBYupJWuyIaytJ+ymDUqvYTqmUBqmcIuiLKC4sGqhADCnKKuwPkzEhMDEqGqlWKqlTJyutWu+qKnCIswIkQvEb8qjKCqcYpy8J5qo/BmkycuiLnCqTAzEelrEuPmjGXqhdcy/HOqhIEqkhfDGXIqbXqq4MqybLjAEhuAB/duwKdy5NeqjqLqlxjoILuClQzChBWDIVpu4hToBwvn/sAUMptLaw9F5pcwZAb46nQp8oKzanlzMyIZAufSKA5AsrMQaAVAbwbe8oMuZsJxMoul5t308oheMyd3JtYJKqIaKqNv5y41KwlEszKEMAzAbxyabr6/MoPOqyDtcr5zqqodqslWKwYeqnHxLriFQnu/6ycvbxNTJoCZ6sQSbyttpsIvcyjw8CGfaoCa7sRHAvBHsz53cxtbMs34aATLgzoMbx+PMARD6nUFszjpb0MtcCActpeu8xAI7yF57todAtjrMwF18wIOgozo8yYwwyUcr0enMn3CKt8y7pyztq32qt3w60YSQ0tFrzyt8CLBcCDP8tI4szUBNr0JNocdK/9BfCqnMmdAnfc7OCbQ4HdEKa59KTdLp6a9TW7XAqptr67Y27MH+Oc31jKD1iaKxyp5DXLe1e6WCTLPO+a7Pqs9R69JNHNcOGqKA7Lt2bambO9Y6TdY5a9EoqszlyaCIrLCGjac2K59I7Z2KO6YfjaNUfLhvLbGNu7OPWwiPzdT+ygIsWqFxjMH+KaUg8K1WeqqiDdL3DNPGSL+GeUEw/LKFY8BqaL+N3Np/vdOjENufAAKFPNtaDH22nY2u7ZfFvY7DjY3HzZfLDZvSm7OJbG4obJq57dczmtzR2b/TTRX7Oa0azMFWGs9y/Qlda9PWXd3b7LnYzb/g6aprS680e//D0bmc243KrF2n6A3YSbveh/qiV8qbp4u2/l3FuAkDIeAC/XnKIu21xDzSiYytspyzs5qbV+zDhara+e2e7Mvfe9u3B5rV8Vmtd6vgC+ulDLvg1iyz2Eyv2FrJYY2qbUuditqd2hmGGZ6LjpnjOr7jEqjb1IqnocqbJz4BvQvkHGCxbuqlwTkETSzKG60JZIut6zkEl3rgcCzjrjqyNn7jXB7SP67J8fzIVMuswunbZ/vNOAqtwzrTNt3VNVywAguq5n3Tk0y5E5qnNd3ONb7FXd7n96zBEx3ggO67g4ADCA7jPSzXCF3aZg0C3W0Ia77UDbvXWb7n8OvnmO7KVOH/whKNo2xOP82d6Z6phZxus58+jKKe6tx8v6re6hqu3K4e6+e9vdQcmbJ+6yPH6fY955rA27KJ68Deb7p+3y9c6+8Y7MC+H+F85Hd84DBa4YmrpQib0OH837kJxUUarLdZoTT8xegppqA6p2rcxrOO7F3eO9KJs779o5hq07xZ1L6csh/Nq7dpvqu8zEQNAz0d4ZHcnc28qMH9vuae2+iOp3MKyAW7piyA5RjdqvKemxSL8M6c8PNKnYeaz2nL2JmtsOk98JmO7r+K0zd9tSz97rmLtVYtsrNqtgs8qNSpoz291RLtuOXu8fndO5SrnG2duixA6dFe4Jrbuni+u2FaYcCbW7ix2qNMPdWYXfM2X92hjq/j+/Tn3mn17bJU3+dR/+tZn+pb/5tdL+pfHzxjH/YxWfbcZvYfz+Nsr4tq//ZwH/dyP/d0X/d2f/d4n/d6v/d83/d+//eAH/iCP/h0HwgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T: testosterone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; ICSI: intracytoplasmic sperm injection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5488=[""].join("\n");
var outline_f5_23_5488=null;
var title_f5_23_5489="Nipple inversion";
var content_f5_23_5489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nipple inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nipple inversion from breast cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harris, JR, Lippman, ME, Morrow, M, Osborne, CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5489=[""].join("\n");
var outline_f5_23_5489=null;
var title_f5_23_5490="Space between rectum and vagina";
var content_f5_23_5490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taking the uterosacral ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharp dissection is used to incise the peritoneum between two uterosacral ligaments, and to develop the potential space between the posterior vagina and the anterior rectum. The uterosacral ligaments are then clamped laterally at their origin and divided, as is the posterior aspect of the parametrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5490=[""].join("\n");
var outline_f5_23_5490=null;
var title_f5_23_5491="Technetium Tc-99m oxidronate: Drug information";
var content_f5_23_5491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m oxidronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/387?source=see_link\">",
"    see \"Technetium Tc-99m oxidronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13210110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Technescan&trade; HDP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13210112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13210119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: 15 mCi (555 MBq); range: 10-20 mCi (370-740 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      SPECT imaging:",
"     </b>",
"     I.V.: 20-30 mCi (740-1110 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13210118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: 0.2 mCi/kg (7.4 MBq/kg); range: 0.2-0.35 mCi/kg (7.4-13 MBq/kg); recommended total minimum dose: 1 mCi (37 MBq); maximum dose: 20 mCi (740 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13210116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skeletal imaging agent to detect areas of altered osteogenesis; occult fracture, osteomyelitis, neoplastic disease, stress fracture, avascular necrosis, bone infarcts, bone graft viability, unexplained bone pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13210122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13210131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypocalcemia: May form complexes with cations (eg, calcium); use with caution in hypocalcemic patients or in patients at risk to develop hypocalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13210136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13210137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13210138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (per manufacturer)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13210139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In one report, 1.9% was excreted in breast milk, resulting in &lt;100 mrem (1 mSv) effective dose to the infant (Ahlgren, 1985); therefore, interruption of breast-feeding is not necessary (Mountford, 1989; U.S. Nuclear Regulatory Commission, 1977).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahlgren L, Ivarsson S, Johansson L, et al, \"Excretion of Radionuclides in Human Breast Milk After the Administration of Radiopharmaceuticals,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 1985, 26(9):1085-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/23/5491/abstract-text/4032049/pubmed\" id=\"4032049\" target=\"_blank\">",
"        4032049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donohoe KJ, Brown ML, Collier BD, et al, \"Society of Nuclear Medicine Procedure Guideline for Bone Scintigraphy,\" 2003. Available at file://interactive.snm.org/docs/pg_ch34_0403.pdf. Last accessed August 31, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mountford PJ and Coakley AJ, \"A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,\"",
"      <i>",
"       Nucl Med Commun",
"      </i>",
"      , 1989, 10(1):15-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/23/5491/abstract-text/2645546/pubmed\" id=\"2645546\" target=\"_blank\">",
"        2645546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Nuclear Regulatory Commission, \"Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,\" 1977.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16815 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5491=[""].join("\n");
var outline_f5_23_5491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210110\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210112\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210119\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210118\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210116\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255277\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210122\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210131\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210136\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210137\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210138\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210139\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/387?source=related_link\">",
"      Technetium Tc-99m oxidronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5492="Nuss repair pectus";
var content_f5_23_5492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Nuss repair of pectus excavatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 701px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5492=[""].join("\n");
var outline_f5_23_5492=null;
var title_f5_23_5493="Shave biopsy depth";
var content_f5_23_5493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Depth of shave biopsies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shave biopsies can be either superficial or deep. Superficial shave biopsies are done across or nearly parallel to the skin surface and extend into the epidermis only or epidermis and limited superficial dermis. The slightly deeper shave biopsy allows for sampling of dermis and epidermis, important for assessing basal cell and squamous cell carcinomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5493=[""].join("\n");
var outline_f5_23_5493=null;
var title_f5_23_5494="Aliskiren and valsartan: Drug information";
var content_f5_23_5494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aliskiren and valsartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/11/13493?source=see_link\">",
"    see \"Aliskiren and valsartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9461184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8774106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valturna&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8775403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Renin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9461232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dose is individualized; combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class). Titrate at 2- to 4-week intervals as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Initial therapy:",
"     </i>",
"     Aliskiren 150 mg and valsartan 160 mg once daily; titrate to effect (maximum daily aliskiren dose: 300 mg; maximum daily valsartan dose: 320 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients not controlled with single-agent therapy:",
"     </i>",
"     Aliskiren 150 mg and valsartan 160 mg once daily; titrate to effect (maximum daily aliskiren dose: 300 mg; maximum daily valsartan dose: 320 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9461233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9461234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9461235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use with caution; clinical experience is limited.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9461248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Valturna&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     150/160: Aliskiren 150 mg and valsartan 160 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     300/320: Aliskiren 300 mg and valsartan 320 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9461186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9461237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time daily; may take with or without a meal, but consistent administration with regards to meal is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8775404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, including use as initial therapy in patients likely to need multiple antihypertensives for adequate control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9461185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Valturna&reg; may be confused with Tekturna&reg;, valsartan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9461201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Frequencies reported with combination product. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (3%), vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Angioedema, periorbital edema, and peripheral edema have been reported with aliskiren.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9461192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9461193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with caution in any patient with a history of angioedema (of any etiology) as angioedema, some cases necessitating hospitalization and intubation, has been observed (rarely) with aliskiren use. Discontinue immediately following any signs and symptoms of angioedema; do not readminister. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Early, aggressive, and appropriate management is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use with caution with these agents; monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with azilsartan/chlorthalidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy, because of valsartan-induced hypotension. Careful monitoring of BUN, serum creatinine, and potassium is necessary especially if preexisting renal disease exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with significant hepatic impairment since valsartan clearance is significantly reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution or avoid in patients with deteriorating renal function or low renal blood flow (eg, renal artery stenosis, severe heart failure); may increase risk of developing acute renal failure and hyperkalemia. Concomitant use of aliskiren with an ACE inhibitor or ARB may increase risk of developing acute renal failure and should be avoided in patients with GFR &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors: Concurrent use of ACE inhibitors may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concurrent use with strong inhibitors of P-glycoprotein (eg, cyclosporine, itraconazole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9461255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9461256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aliskiren may enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Aliskiren. Canagliflozin may enhance the hypotensive effect of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Aliskiren may decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Aliskiren. Management: Avoid concomitant use of aliskiren and grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction. Monitor for decreased aliskiren levels/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9461204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: High-fat meals decrease absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9461188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9461189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9461190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9461191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9461236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; however, a high-fat meal reduces absorption. Avoid salt substitutes which contain potassium.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9461239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum electrolytes, BUN, serum creatinine; in HF, serum potassium during dose escalation and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9461224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Aliskiren is a direct renin inhibitor, resulting in blockade of the conversion of angiotensinogen to angiotensin I. Angiotensin I suppression decreases the formation of angiotensin II (Ang II), a potent blood pressure-elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Valsartan produces direct antagonism of the angiotensin II (AT2) receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9461226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/23/5494/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8572 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5494=[""].join("\n");
var outline_f5_23_5494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461184\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774106\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775403\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461232\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461233\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461234\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461235\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461237\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775404\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461185\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461201\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461192\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461193\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461255\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461256\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461204\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461188\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461189\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461190\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461191\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461236\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461239\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461224\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461226\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/11/13493?source=related_link\">",
"      Aliskiren and valsartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5495="Evaluation and diagnosis of infantile hemangiomas";
var content_f5_23_5495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and diagnosis of infantile hemangiomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Denise W Metry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5495/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/23/5495/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile hemangiomas are benign tumors of vascular endothelium. They are the most common tumors of childhood. Despite their benign and self-limited nature, some hemangiomas can cause complications such as ulceration or life-altering disfigurement. Occasionally, hemangiomas may compromise vital organ function or may occur in association with developmental anomalies.",
"   </p>",
"   <p>",
"    The evaluation of hemangiomas will be discussed here. The epidemiology, pathogenesis, clinical features, complications, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the vast majority of cases the diagnosis of a hemangioma can be established clinically, based upon the history and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/1\">",
"     1",
"    </a>",
"    ]. However, deeper subcutaneous lesions without the characteristic overlying skin changes and hepatic lesions (especially in the absence of a cutaneous hemangioma) may be very difficult to distinguish from vascular malformations or other tumors. Although imaging studies can be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], tissue biopsy is generally needed for definitive diagnosis in concerning cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history for a child with a vascular lesion include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age at which the lesion was first noted and subsequent behavior of the lesion.",
"     </li>",
"     <li>",
"      Presence of ulceration, pain, bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of secondary infection.",
"     </li>",
"     <li>",
"      Whether any imaging studies, biopsies, or other prior evaluations (including subspecialty) have been performed.",
"     </li>",
"     <li>",
"      Previous treatment and response.",
"     </li>",
"     <li>",
"      Progressive respiratory difficulty in the first several months of life, particularly if a hemangioma is in a cervicofacial, mandibular, or \"beard\" distribution (",
"      <a class=\"graphic graphic_picture graphicRef58168 \" href=\"UTD.htm?18/23/18815\">",
"       picture 1",
"      </a>",
"      ) (may indicate the simultaneous presence of airway hemangioma).",
"     </li>",
"     <li>",
"      Signs of high-output cardiac failure during infancy in the presence of multiple (five or more) cutaneous hemangiomas (may indicate the presence of hepatic hemangiomas).",
"     </li>",
"     <li>",
"      Rapid growth, along with tenseness, purpuric appearance, or widespread telangiectasias in the presence of a very low platelet count (may indicate the Kasabach-Merritt phenomenon in the case of a kaposiform hemangioendothelioma or tufted angioma &ndash; vascular tumors distinct from infantile hemangiomas).",
"     </li>",
"     <li>",
"      Any parental preconceptions: What have they already learned about the potential diagnosis and treatment options? What concerns them the most about their child's lesion(s)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful examination of the skin and mucous membranes",
"     </li>",
"     <li>",
"      Documentation of lesion morphology and location, and approximate size",
"     </li>",
"     <li>",
"      Documentation of the presence and severity of ulceration, and whether there is evidence of secondary infection",
"     </li>",
"     <li>",
"      Palpation of the liver for hepatomegaly and evaluation for abdominal bruit if clinically indicated, including evaluation for signs of high-output heart failure (eg, tachycardia, wide pulse pressure, bounding pulses, midsystolic murmur,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a third heart sound caused by the increased rate of ventricular filling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Additional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hemangiomas can be diagnosed clinically without additional studies. In the minority of cases where the diagnosis is in question, imaging (ultrasonography, computed tomography [CT], or magnetic resonance (MR) imaging) can be helpful, but should not be relied upon if there is any question of malignancy, in which case tissue biopsy is generally necessary. Imaging may also be useful in evaluating the extent of a complicated hemangioma, evaluating for other potential anomalies when clinically indicated (eg, PHACE syndrome), or following response to therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Additional evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the location and morphology of the hemangioma, additional evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Periorbital hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periorbital hemangiomas may compromise normal visual development (",
"    <a class=\"graphic graphic_picture graphicRef50631 \" href=\"UTD.htm?41/12/42181\">",
"     picture 2",
"    </a>",
"    ). In concerning cases, early examination by an ophthalmologist familiar with the evaluation and treatment of periorbital hemangiomas is mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/7\">",
"     7",
"    </a>",
"    ]. The management of periorbital hemangiomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Segmental hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental hemangiomas are usually plaque-like and demonstrate linear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    geographic patterning (",
"    <a class=\"graphic graphic_picture graphicRef82212 \" href=\"UTD.htm?16/51/17200\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar to multiple cutaneous hemangiomas, segmental hemangiomas may also be associated with visceral hemangiomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The locations of visceral lesions often correlate with the sites of cutaneous lesions. Visceral hemangiomas undergo spontaneous involution as do their cutaneous counterparts, probably most often without sequelae. For this reason, evaluation of infants with segmental hemangiomas depends upon the anatomic location and, most importantly, the presence of clinical signs and symptoms as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/10\">",
"     10",
"    </a>",
"    ]. Imaging of asymptomatic",
"    <strong>",
"    </strong>",
"    infants with segmental hemangiomas for visceral hemangiomatosis is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of the expense and need for general anesthesia in young infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Beard distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with segmental hemangiomas in the cervicofacial mandibular or \"beard\" distribution (",
"    <a class=\"graphic graphic_picture graphicRef58168 \" href=\"UTD.htm?18/23/18815\">",
"     picture 1",
"    </a>",
"    ) should be clinically monitored for signs of airway involvement (eg, hoarseness, stridor) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/11\">",
"     11",
"    </a>",
"    ]. The possibility of PHACE syndrome should also be considered in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13165020\">",
"    <span class=\"h3\">",
"     PHACE syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with large, segmental hemangiomas, particularly when located on the face or scalp, are at risk for PHACE syndrome (",
"    <a class=\"graphic graphic_table graphicRef80245 \" href=\"UTD.htm?9/52/10059\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70599 \" href=\"UTD.htm?18/46/19174\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The clinical features of PHACE syndrome are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'Clinical features'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infants at risk for PHACE syndrome should undergo careful cutaneous, ophthalmologic, cardiac, and neurologic evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Even in asymptomatic infants, MR imaging with angiography of the head and neck is indicated, especially given the potential for stroke or other complications secondary to progressive vasculopathy in a subset of infants with PHACE syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The comprehensive evaluation should take place before initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of infantile hemangiomas\", section on 'Use in PHACE syndrome'",
"    </a>",
"    .) The risk of adverse events related to cardiovascular anomalies in PHACE syndrome is currently unknown. Imaging of the aortic arch to identify abnormalities should be performed.",
"   </p>",
"   <p>",
"    Hearing loss (conductive or sensorineural) has been reported in patients with PHACE syndrome, particularly in those with hemangiomas involving the ear and periauricular skin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/20\">",
"     20",
"    </a>",
"    ]. This may be related to the presence of ipsilateral intracranial hemangiomas involving auditory structures. Children with PHACE and hemangiomas in the periauricular area should be evaluated with both MR imaging and audiometric testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lumbosacral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental hemangiomas over the midline lumbosacral spine (",
"    <a class=\"graphic graphic_picture graphicRef72298 \" href=\"UTD.htm?17/3/17471\">",
"     picture 5",
"    </a>",
"    ), may be associated with spinal dysraphism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anal or genitourinary anomalies, including tethered spinal cord, imperforate anus with fistula formation, bony anomalies of the sacrum, abnormal genitalia, renal abnormalities, or lipomyelomeningocele [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/21-27\">",
"     21-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MR imaging is the most sensitive means of definitive diagnosis of spinal anomalies and should be performed in all infants or older children with a segmental hemangioma over the lumbosacral spine.",
"   </p>",
"   <p>",
"    Screening of patients with midline hemangiomas in the lumbosacral area is supported by the results of a multicenter, prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/28\">",
"     28",
"    </a>",
"    ]. In this study, MR imaging detected spinal anomalies in 21 out of 41 children (51 percent) with localized or segmental lumbosacral hemangiomas that were greater than or equal to 2.5 cm in size (RR=640, 95% CI 404-954). The study did not evaluate imaging in patients with smaller lesions, and it is unclear whether these results translate to patients with small, localized hemangiomas. A retrospective study evaluated the types of spinal dysraphism in children with lumbosacral hemangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/27\">",
"     27",
"    </a>",
"    ]. Among 20 children with lumbosacral hemangioma and spinal dysraphism, 12 had tethered cord, 10 spinal lipoma or lipomyelomeningocele, 9 intraspinal hemangiomas, and 8 sinus tract [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike MR imaging, ultrasonographic examination does not require sedation in infants. Some authors have suggested that ultrasonography can be performed instead of MR imaging in infants younger than four months of age if expertise in pediatric ultrasonography is available [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/22,23,25\">",
"     22,23,25",
"    </a>",
"    ]. However, ultrasounds may miss some spinal abnormalities. In the cohort study described above, 5 out of 12 patients (42 percent) with normal ultrasound examinations subsequently were noted to have spinal anomalies on MR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/28\">",
"     28",
"    </a>",
"    ]. The average age of patients who received ultrasounds in the study was two months. The sensitivity and specificity of ultrasonography were 50 (95% CI, 19-81) and 78 (95% CI, 40-97) percent, respectively. Another prospective study also found that ultrasounds failed to detect spinal dysraphism in some patients; the diagnosis was missed in 15 percent of infants under the age of six months who had hemangiomas or lipomas overlying the involved area [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, MR imaging remains the gold standard for evaluating patients with lumbosacral hemangiomas for underlying spinal disorders. In young infants, ultrasonography can be used as an initial test and MR imaging can be delayed until the age of four to six months if there are no clinical findings that indicate the need for earlier evaluation (patent sinus tracts, ulceration, or neurologic signs or symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Multiple hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of infants have more than one hemangioma, but only 3 percent have six or more lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/30\">",
"     30",
"    </a>",
"    ]. Multifocal cutaneous hemangiomas at-risk for concomitant visceral hemangiomas (ie, diffuse neonatal hemangiomatosis [DNH]) are defined as &ge;5 small, localized lesions. The liver is the extracutaneous site most frequently involved, whereas involvement of other sites, such as the gastrointestinal tract or the brain, is exceedingly rare. In most cases, hepatic hemangiomas are asymptomatic and only rarely cause major complications.",
"   </p>",
"   <p>",
"    Infants with two or three cutaneous hemangiomas do not require further visceral evaluation or monitoring if findings on physical examination are normal (with the exception of the cutaneous hemangiomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, it is generally recommended that infants younger than six months with &ge;5 cutaneous hemangiomas undergo early evaluation with abdominal ultrasound and be monitored clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This recommendation is supported by a prospective study, in which 16 percent of infants with &ge;5 hemangiomas had solitary or multiple hepatic hemangiomas and 1.3 percent had airway or gastrointestinal hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/34\">",
"     34",
"    </a>",
"    ]. None of the children with &le;4 cutaneous hemangiomas had visceral lesions. Only one child with hepatic hemangioma was symptomatic with hepatomegaly and high-output congestive heart failure and required treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and oral corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Large hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk for hepatic hemangiomas in infants with large hemangiomas has been suggested in two small retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/10,35\">",
"     10,35",
"    </a>",
"    ]. In contrast, a prospective study found no hepatic hemangiomas in 60 infants with at least one hemangioma &gt;30 cm",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/36\">",
"     36",
"    </a>",
"    ]. It remains unclear whether infants with large hemangiomas should be routinely screened for hepatic hemangiomas with ultrasonography purely based upon lesion size. However, if signs or symptoms that suggest hepatic hemangiomas (poor growth or feeding, tachypnea, cardiac murmur, abdominal distension, or hepatomegaly) are present, further evaluation is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the diagnosis of infantile hemangiomas can be made on the basis of history and physical examination in the vast majority of cases. Cases in which the diagnosis may be difficult include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early segmental hemangiomas, within the first few days to weeks of life before significant proliferation occurs, may be initially difficult to distinguish from a capillary vascular malformation (ie, port-wine stain) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/21\">",
"       21",
"      </a>",
"      ]. Early arteriovenous malformations of the skin can also present as a cutaneous \"blush\" that is often initially misdiagnosed as a capillary malformation.",
"     </li>",
"     <li>",
"      Large vascular lesions that are congenital (ie, \"fully developed\" at birth) are probably not true infantile hemangiomas. The differential diagnosis includes vascular malformations, rapidly involuting or non-involuting congenital \"hemangiomas\", or other benign and malignant vascular tumors, diagnoses that can often be made clinically by a specialist familiar with such entities [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/21,38,39\">",
"       21,38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapidly proliferating, violaceous tumors in the setting of the Kasabach-Merritt phenomenon are not infantile hemangiomas, but one of two other benign but sometimes aggressive vascular tumors: kaposiform hemangioendothelioma (most commonly) or tufted angioma.",
"     </li>",
"     <li>",
"      Deep, subcutaneous tumors, particularly when no overlying skin changes are present to assist with diagnosis, should be suspect, as should any vascular lesion with an atypical clinical appearance or unusual behavior. Although imaging may be helpful, tissue biopsy is generally necessary in concerning cases in order to exclude malignancy.",
"     </li>",
"     <li>",
"      Hepatic hemangiomas may be very difficult to distinguish from vascular (particularly arterio-venous) malformations or other tumors, especially in infants without cutaneous hemangiomas. Radiologic imaging may help in making this distinction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyogenic granuloma (",
"      <a class=\"graphic graphic_picture graphicRef67395 \" href=\"UTD.htm?23/19/23859\">",
"       picture 6",
"      </a>",
"      ) is an acquired lesion that is generally small (often less than 1 cm) and develops on the face or upper trunk in a preschool or school-aged child. Lesions are often friable and complicated by recurrent bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other lesions that can occasionally mimic infantile hemangiomas include plexiform neurofibroma, infantile fibrosarcoma, rhabdomyosarcoma, nasal glioma, dermoid cysts, and myofibromas [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5495/abstract/6,37\">",
"       6,37",
"      </a>",
"      ]. These lesions generally have a distinct clinical and histologic appearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Referral to an appropriate and experienced specialist is indicated for the following infants and children: those in whom the diagnosis is in question, those who have actual or potential organ complications, particularly when the lesion is segmental,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those for whom systemic therapy is being considered. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with periorbital hemangiomas at-risk for visual compromise (",
"      <a class=\"graphic graphic_picture graphicRef82212 \" href=\"UTD.htm?16/51/17200\">",
"       picture 3",
"      </a>",
"      ) should be referred to an ophthalmologist familiar with the evaluation and treatment of periorbital hemangiomas. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Periorbital hemangiomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with a segmental cutaneous hemangioma in a cervicofacial mandibular or \"beard\" distribution (",
"      <a class=\"graphic graphic_picture graphicRef58168 \" href=\"UTD.htm?18/23/18815\">",
"       picture 1",
"      </a>",
"      ) should be monitored carefully during infancy for signs of respiratory distress and should be evaluated for PHACE syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Beard distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13165020\">",
"       'PHACE syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and children with segmental hemangiomas overlying the midline lumbosacral spine (",
"      <a class=\"graphic graphic_picture graphicRef72298 \" href=\"UTD.htm?17/3/17471\">",
"       picture 5",
"      </a>",
"      ) should be evaluated for spinal dysraphism with MR imaging. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Lumbosacral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with segmental hemangiomas, particularly when located on the face (",
"      <a class=\"graphic graphic_picture graphicRef70599 \" href=\"UTD.htm?18/46/19174\">",
"       picture 4",
"      </a>",
"      ), are at risk for PHACE syndrome (",
"      <a class=\"graphic graphic_table graphicRef80245 \" href=\"UTD.htm?9/52/10059\">",
"       table 1",
"      </a>",
"      ) and should undergo careful cutaneous, ophthalmologic, cardiac, and neurologic evaluations. Even in asymptomatic infants, imaging and angiography of the head, neck, and aortic arch is indicated, particularly given the possibility for progressive vascular occlusive disease (ie, stroke) in infants with cerebrovascular anomalies. It is also recommended that infants at risk for PHACE be completely evaluated before initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H13165020\">",
"       'PHACE syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of infantile hemangiomas\", section on 'Use in PHACE syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants younger than 6 months with &ge;5 small cutaneous hemangiomas should undergo ultrasonography of the abdomen for potential liver hemangiomas and be monitored clinically. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Multiple hemangiomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/1\">",
"      Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg 1983; 18:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/2\">",
"      Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/3\">",
"      Burrows PE, Laor T, Paltiel H, Robertson RL. Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin 1998; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/4\">",
"      Dubois J, Garel L, Grignon A, et al. Imaging of hemangiomas and vascular malformations in children. Acad Radiol 1998; 5:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/5\">",
"      Paltiel HJ, Burrows PE, Kozakewich HP, et al. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology 2000; 214:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/6\">",
"      Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/7\">",
"      Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Pediatr 1996; 26:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/8\">",
"      Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/9\">",
"      Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002; 138:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/10\">",
"      Metry DW, Hawrot A, Altman C, Frieden IJ. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004; 140:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/11\">",
"      Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a \"beard\" distribution. J Pediatr 1997; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     PHACE Association. Online Mendelian Inheritance in Man (OMIM) website. OMIM entry #606519. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/13\">",
"      Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. J Pediatr 2001; 139:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/14\">",
"      Haggstrom AN, Garzon MC, Baselga E, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010; 126:e418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/15\">",
"      Metry D, Heyer G, Hess C, et al. Consensus Statement on Diagnostic Criteria for PHACE Syndrome. Pediatrics 2009; 124:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/16\">",
"      Metry DW, Garzon MC, Drolet BA, et al. PHACE Syndrome: Current Knowledge, Future Directions. Proceedings of a Research Conference. Pediatric Dermatology (in press).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/17\">",
"      Bhattacharya JJ, Luo CB, Alvarez H, et al. PHACES syndrome: a review of eight previously unreported cases with late arterial occlusions. Neuroradiology 2004; 46:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/18\">",
"      Burrows PE, Robertson RL, Mulliken JB, et al. Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: report of eight patients. Radiology 1998; 207:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/19\">",
"      Drolet BA, Dohil M, Golomb MR, et al. Early stroke and cerebral vasculopathy in children with facial hemangiomas and PHACE association. Pediatrics 2006; 117:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/20\">",
"      Duffy KJ, Runge-Samuelson C, Bayer ML, et al. Association of hearing loss with PHACE syndrome. Arch Dermatol 2010; 146:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/21\">",
"      Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/22\">",
"      Goldberg NS, Hebert AA, Esterly NB. Sacral hemangiomas and multiple congenital abnormalities. Arch Dermatol 1986; 122:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/23\">",
"      McAtee-Smith J, Hebert AA, Rapini RP, Goldberg NS. Skin lesions of the spinal axis and spinal dysraphism. Fifteen cases and a review of the literature. Arch Pediatr Adolesc Med 1994; 148:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/24\">",
"      Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics 1989; 83:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/25\">",
"      Tubbs RS, Wellons JC 3rd, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg 2004; 100:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/26\">",
"      Girard C, Bigorre M, Guillot B, Bessis D. PELVIS Syndrome. Arch Dermatol 2006; 142:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/27\">",
"      Schumacher WE, Drolet BA, Maheshwari M, et al. Spinal dysraphism associated with the cutaneous lumbosacral infantile hemangioma: a neuroradiological review. Pediatr Radiol 2012; 42:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/28\">",
"      Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr 2010; 157:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/29\">",
"      Sardana K, Gupta R, Garg VK, et al. A prospective study of cutaneous manifestations of spinal dysraphism from India. Pediatr Dermatol 2009; 26:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/30\">",
"      Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/31\">",
"      Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr 1996; 129:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/32\">",
"      Dickie B, Dasgupta R, Nair R, et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg 2009; 44:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/33\">",
"      Kulungowski AM, Alomari AI, Chawla A, et al. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012; 47:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/34\">",
"      Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol 2011; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/35\">",
"      Hughes JA, Hill V, Patel K, et al. Cutaneous haemangioma: prevalence and sonographic characteristics of associated hepatic haemangioma. Clin Radiol 2004; 59:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/36\">",
"      Horii KA, Drolet BA, Baselga E, et al. Risk of hepatic hemangiomas in infants with large hemangiomas. Arch Dermatol 2010; 146:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/37\">",
"      Garzon MC, Frieden IJ. Hemangiomas: when to worry. Pediatr Ann 2000; 29:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/38\">",
"      Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 2001; 107:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/39\">",
"      Rogers M, Lam A, Fischer G. Sonographic findings in a series of rapidly involuting congenital hemangiomas (RICH). Pediatr Dermatol 2002; 19:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5495/abstract/40\">",
"      Frieden IJ, Esterly NB. Pyogenic granulomas of infancy masquerading as strawberry hemangiomas. Pediatrics 1992; 90:989.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5793 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5495=[""].join("\n");
var outline_f5_23_5495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Additional studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Periorbital hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Segmental hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Beard distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13165020\">",
"      - PHACE syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lumbosacral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Multiple hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Large hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5793|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/23/18815\" title=\"picture 1\">",
"      Beard distribution hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/12/42181\" title=\"picture 2\">",
"      Periocular hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/51/17200\" title=\"picture 3\">",
"      Segmental hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/46/19174\" title=\"picture 4\">",
"      PHACE syndrome 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17471\" title=\"picture 5\">",
"      Lumbosacral hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23859\" title=\"picture 6\">",
"      Pyogenic granuloma - chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/52/10059\" title=\"table 1\">",
"      PHACE syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5496="Approach to the child with leukocoria";
var content_f5_23_5496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with leukocoria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Paul L Kaufman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5496/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/23/5496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term leukocoria means \"white pupil\" (from the Greek \"leukos\" meaning white and \"kore\" meaning pupil) and is the name given to the clinical finding of a white pupillary reflex (",
"    <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"     picture 1",
"    </a>",
"    ). Leukocoria can be caused by abnormalities in the lens (eg, cataract), vitreous (eg, hemorrhage), or retina (eg, retinoblastoma) (",
"    <a class=\"graphic graphic_table graphicRef73809 \" href=\"UTD.htm?11/25/11677\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It can be the initial manifestation of a wide spectrum of intraocular and systemic disease processes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. The differential diagnosis can be narrowed through a complete clinical and family history and a thorough ophthalmic examination.",
"   </p>",
"   <p>",
"    Although transient leukocoria is occasionally caused by the reflection of a normal optic disc, all children with newly discovered leukocoria should be referred promptly to an ophthalmologist to exclude retinoblastoma and other life- or sight-threatening conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation and management of the child with leukocoria and a brief discussion of the common causes of leukocoria in children are presented here. Retinoblastoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link\">",
"     \"Overview of retinoblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF LEUKOCORIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common causes of leukocoria in children include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/3-7,9,10\">",
"     3-7,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retinoblastoma (47 percent of cases in one series) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Persistent fetal vasculature",
"     </li>",
"     <li>",
"      Retinopathy of prematurity",
"     </li>",
"     <li>",
"      Cataract",
"     </li>",
"     <li>",
"      Coloboma (fissure or cleft) of choroid or optic disc",
"     </li>",
"     <li>",
"      Uveitis",
"     </li>",
"     <li>",
"      Toxocariasis",
"     </li>",
"     <li>",
"      Coats disease",
"     </li>",
"     <li>",
"      Vitreous hemorrhage",
"     </li>",
"     <li>",
"      Retinal dysplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Retinoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoblastoma (",
"    <a class=\"graphic graphic_picture graphicRef71468 \" href=\"UTD.htm?42/47/43761\">",
"     picture 2",
"    </a>",
"    ) is the most common intraocular tumor of childhood, occurring in approximately 1 in 15,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/11\">",
"     11",
"    </a>",
"    ]. The annual incidence is 11 per million in children from birth to four years of age and 0.6 per million in children five years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/12\">",
"     12",
"    </a>",
"    ]. The average age at the time of diagnosis is two years in unilateral cases and one year in bilateral cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link\">",
"     \"Overview of retinoblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leukocoria is the most common presenting finding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/14\">",
"     14",
"    </a>",
"    ]. Other findings may include strabismus, decreased vision, ocular inflammation, family history of retinoblastoma, vitreous hemorrhage, hyphema, orbital cellulitis, proptosis, glaucoma, eye pain, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/14\">",
"     14",
"    </a>",
"    ]. The diagnosis of retinoblastoma is usually made on the basis of clinical examination and the presence of calcification on computed tomography (CT) or ocular ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Persistent fetal vasculature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent fetal vasculature (PFV, formerly called persistent hyperplastic primary vitreous [PHPV]) results from a failure of the embryonic primary vitreous and hyaloid vascular system to involute during gestation. The posterior form is characterized by the presence of a rudimentary vascular stalk in the vitreous that usually extends to the optic nerve and is associated with a plaque-like opacity in the posterior lens. It is typically unilateral; bilateral lesions may be associated with trisomy 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ]. The involved eye is usually mildly microphthalmic with a shallow anterior chamber, prominent vessels on the iris, elongated ciliary processes, and vascularized white retrolental tissue (",
"    <a class=\"graphic graphic_picture graphicRef75788 \" href=\"UTD.htm?21/26/21922\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/10\">",
"     10",
"    </a>",
"    ]. Children with PFV may go on to develop glaucoma, cataract, intraocular hemorrhage, or retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Retinopathy of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy of prematurity (ROP) is a developmental vascular proliferative disorder that occurs in the incompletely vascularized retina of premature infants and can lead to retinal detachment. ROP affects a substantial number of premature infants, and its incidence increases with decreasing gestational age and birth weight. Other risk factors for ROP include assisted ventilation for longer than one week, surfactant therapy, high blood transfusion volume, sepsis, fluctuations in blood gas measurements, intraventricular hemorrhage, bronchopulmonary dysplasia, and elevated arterial oxygen tension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. ROP causes leukocoria only when ROP is severe and results in retinal detachment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cataract",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cataract is an opacity of the lens of the eye that can cause partial or total blindness if not diagnosed and treated promptly. Congenital cataracts may be present at birth or appear in early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autosomal dominant inheritance is the most commonly identified cause of cataracts in children. Cataracts may be associated with congenital infections (eg, rubella, toxoplasmosis, herpes simplex virus, cytomegalovirus [CMV]). Cataracts also can develop in children who have various systemic, genetic, or metabolic conditions (eg, diabetes mellitus, Turner syndrome, Down syndrome, galactosemia, peroxisomal disorders) or who are exposed to high-dose, long-term systemic corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ]. (See appropriate topic reviews). In addition, cataracts may develop in children who have uveitis or sustain ocular trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Optic disc abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital and acquired abnormalities of the optic disc, such as optic disc coloboma (",
"    <a class=\"graphic graphic_picture graphicRef54267 \" href=\"UTD.htm?1/27/1457\">",
"     picture 4",
"    </a>",
"    ), morning glory disc (",
"    <a class=\"graphic graphic_picture graphicRef55325 \" href=\"UTD.htm?39/31/40433\">",
"     picture 5",
"    </a>",
"    ), myelinated nerve fibers (",
"    <a class=\"graphic graphic_picture graphicRef75087 \" href=\"UTD.htm?9/55/10096\">",
"     picture 6",
"    </a>",
"    ), and malignant infiltration (",
"    <a class=\"graphic graphic_picture graphicRef67467 \" href=\"UTD.htm?8/1/8210\">",
"     picture 7",
"    </a>",
"    ) also can produce leukocoria. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of the iris, ciliary body,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    choroid can cause leukocoria due to abnormal retinal reflection, the presence of inflammatory cells and debris in the vitreous, or the development of secondary cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. Uveitis is an occasional cause of leukocoria in patients with inflammatory or infectious retinal diseases such as toxocariasis, toxoplasmosis, or CMV retinitis. A more common mechanism is the abnormal white or off-white reflection of the lesion itself (eg, toxocariasis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Toxocariasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocariasis, or visceral larva migrans, is an infection caused by the dog ascarid",
"    <em>",
"     Toxocara canis",
"    </em>",
"    or, less commonly, the cat ascarid",
"    <em>",
"     Toxocara catis",
"    </em>",
"    . It occurs most commonly in children one to five years of age. Ocular involvement may be the sole manifestation of disease, often presenting in those without an antecedent history of symptomatic visceral larva migrans. The ocular lesion is caused by the inflammatory response to the second-stage larva, which may localize in the eye. Two characteristic lesions may result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A whitish subretinal granuloma measuring one to two disc diameters and located anywhere in the retina; this lesion can cause leukocoria even in the absence of significant uveitis (",
"      <a class=\"graphic graphic_picture graphicRef54982 \" href=\"UTD.htm?15/47/16113\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A large inflammatory mass (nematode endophthalmitis) with prominent vitreous inflammation (",
"      <a class=\"graphic graphic_picture graphicRef54982 \" href=\"UTD.htm?15/47/16113\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either of these lesions may be confused with retinoblastoma, particularly if there is associated calcification. Common presenting signs are strabismus and poor vision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=see_link\">",
"     \"Toxocariasis: visceral and ocular larva migrans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coats disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coats disease is characterized by idiopathic retinal telangiectasias and retinal exudation that can cause retinal detachment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66416 \" href=\"UTD.htm?38/3/38962\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/20\">",
"     20",
"    </a>",
"    ]. It is usually unilateral and has a bimodal distribution, primarily affecting males less than 18 years of age and middle-aged men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. Presenting complaints include decreased visual acuity, strabismus, or leukocoria. Coats disease appears to be caused by somatic mutation in the NDP gene, resulting in a deficiency of norrin (the protein product of the NDP gene) within the developing retina [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vitreous hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitreous hemorrhage causes leukocoria when there is extensive organization of the blood into a clot before degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/9\">",
"     9",
"    </a>",
"    ]. Vitreous hemorrhage can occur in a number of conditions, including [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic disease of the newborn",
"     </li>",
"     <li>",
"      Advanced ROP",
"     </li>",
"     <li>",
"      Persistent fetal vasculature",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Leukemia or other blood dyscrasias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trauma, including intentional trauma (eg, nonaccidental head injury) is the most common cause of vitreous hemorrhage in young children. In the appropriate clinical context, vitreous hemorrhage may be diagnostic of nonaccidental injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Retinal dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal dysplasia refers to the abnormal development of retinal tissue or cells with retention of some features resembling normal structures. It implies aberrant differentiation in any of the cellular layers and is often associated with the formation of rosettes of circular or oval groupings of dysplastic retinal cells. The rosettes are highly variable in shape and size (unlike those in retinoblastoma, which are uniform in size). In many cases, retinal dysplasia is associated with retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal dysplasia may be caused by intrauterine insults or infection. In addition, it occurs in some genetic diseases such as trisomy 13, trisomy 18, and Norrie disease. Norrie disease is an X-linked disorder associated with microcephaly, congenital blindness, deafness, and progressive neuropsychiatric illness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Ocular findings include bilateral retinal detachment without anterior segment abnormalities, features that help to distinguish it from PFV or cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for leukocoria (",
"    <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"     picture 1",
"    </a>",
"    ) is part of the routine visual examination performed by the primary care practitioner at health maintenance visits (",
"    <a class=\"graphic graphic_table graphicRef62277 \" href=\"UTD.htm?14/43/15037\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H12#H12\">",
"     \"The pediatric physical examination: HEENT\", section on 'Eyes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The method of detection of leukocoria depends upon the age of onset. Asymmetry of the red reflex during examination with a direct ophthalmoscope or other focused light source is the typical finding when leukocoria is present at birth or during the first year of life (",
"    <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/26\">",
"     26",
"    </a>",
"    ]. In older children, as well as infants, the asymmetry may be noticed in photographs in which the child has one red and one white pupil (",
"    <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"     picture 1",
"    </a>",
"    ). Because of the optics of the eye, even small retinal lesions or the optic disc itself can produce an abnormal pupillary reflection when the image of the light source falls exactly on that location. Leukocoria may therefore be intermittent and gaze-dependent if it is caused by a localized retinal lesion (such as retinoblastoma), particularly if located in the peripheral fundus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete medical and family history and review of systems are necessary in the evaluation of a child with leukocoria.",
"   </p>",
"   <p>",
"    The following information should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal and birth history &ndash; This should include information regarding exposure to toxins (eg, alcohol), infection (eg, rubella, toxoplasmosis, herpes simplex virus, cytomegalovirus), and medication (corticosteroids or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      ) during the pregnancy, as well as prenatal complications and delivery history.",
"     </li>",
"     <li>",
"      Postnatal course &ndash; This should include information regarding neonatal infection, history of admission to the neonatal intensive care unit, oxygen exposure, and medication history for both the child and the mother.",
"     </li>",
"     <li>",
"      Detailed history of medical illnesses since birth.",
"     </li>",
"     <li>",
"      Exposure to puppies or kittens, and history of pica or geophagia (eating dirt), because these may predispose to toxocariasis or toxoplasmosis.",
"     </li>",
"     <li>",
"      Current medications, particularly corticosteroids, which may cause cataracts.",
"     </li>",
"     <li>",
"      Detailed family history &ndash; The construction of a family tree is helpful in complex cases and should include specific reasons for illness or mortality in all family members. Detailed questions should address history of retinoblastoma or other eye tumors; eye loss; cancer (particularly osteogenic sarcoma, which has a strong association with retinoblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]); and fetal loss or miscarriage.",
"     </li>",
"     <li>",
"      Growth pattern, including history of weight loss or failure to thrive (weight loss or failure to thrive may be indications of metabolic or systemic illness, including retinoblastoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Development (abnormal development is a feature of some of the systemic conditions that can cause leukocoria).",
"     </li>",
"     <li>",
"      Review of systems &ndash; Parents may recall certain medical problems only after being specifically questioned. As examples, a history of hearing loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac conditions may indicate congenital rubella infection; endocrine problems are sometimes associated with optic disc coloboma; HIV infection is associated with chorioretinitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, because patients with leukocoria may need surgical, medical, or chemotherapy for the underlying problem, it is important to inquire about drug allergies, history of surgery (particularly reactions to anesthesia), and immunization status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the child with leukocoria should include evaluation for additional signs of the various conditions associated with leukocoria. As an example, an infant who has a cataract caused by galactosemia may have jaundice, failure to thrive, and hepatosplenomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    .) Areas that require particular attention include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment for dysmorphic features",
"     </li>",
"     <li>",
"      Growth parameters, including head circumference",
"     </li>",
"     <li>",
"      Evaluation of the skin for signs of coagulopathy or trauma",
"     </li>",
"     <li>",
"      Evaluation for organomegaly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary care provider typically performs age-appropriate vision assessment, external ophthalmologic examination, evaluation of muscle balance and alignment, and evaluation of the pupils before referral to an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H12#H12\">",
"     \"The pediatric physical examination: HEENT\", section on 'Eyes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These aspects of the examination will be repeated by the ophthalmologist, who will also perform a dilated funduscopic examination (under anesthesia if necessary) and slit lamp examination, and arrange additional evaluation (eg, radiologic imagining) as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with newly-discovered leukocoria, not obviously associated with serious ocular trauma, has retinoblastoma until proven otherwise. Thus, prompt referral to an ophthalmologist (pediatric ophthalmologist or vitreoretinal specialist, if possible) is essential for",
"    <strong>",
"     all",
"    </strong>",
"    children with leukocoria at the time of initial diagnosis. Patients with unequivocal leukocoria should be examined by an ophthalmologist within one week of detection, and sooner when practical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OPHTHALMOLOGIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologist performs a comprehensive ophthalmologic examination, beginning with age-appropriate vision assessment and external examination. Anterior segment and dilated funduscopic examination are performed next, although comprehensive examination in a young child may be difficult, even for the most experienced clinician. Some children referred with leukocoria require radiologic testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination under anesthesia (EUA) to establish a definitive diagnosis or plan treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     External examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external examination includes assessment for the presence or absence of proptosis, eyelid edema (a sign of trauma, inflammation, or infection), orbital masses, resistance of the globe to retropulsion, lymphadenopathy (preauricular, submandibular, anterior cervical, supraclavicular), and signs of trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Muscle balance and alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye movements are observed for any abnormalities (eg, tropias or phorias), which may indicate orbital trauma or intracranial tumor (eg, dorsal midbrain syndrome and concomitant primitive neuroectodermal tumor [PNET], also known as \"trilateral retinoblastoma\", since it usually occurs in association with bilateral retinoblastoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H9#H9\">",
"     \"Supranuclear disorders of gaze in children\", section on 'Parinaud syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link\">",
"     \"Overview of retinoblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of strabismus in children\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pupils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pupils are examined for reactivity, the presence of a relative afferent defect (Marcus-Gunn pupil), and cataracts.",
"   </p>",
"   <p>",
"    To examine for afferent pupillary defect, a sign of optic neuropathy, the swinging-flashlight test is performed. A penlight is moved slowly from pupil to pupil while the child looks at a distant target. Direct stimulation of a normal eye causes constriction of both pupils. In contrast, direct stimulation of the eye with optic neuropathy results in dilation of both pupils (",
"    <a class=\"graphic graphic_figure graphicRef71937 \" href=\"UTD.htm?41/15/42239\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H35#H35\">",
"     \"The detailed neurologic examination in adults\", section on 'Afferent pupillary defect'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination for cataracts should take place in a darkened room and can be performed with a penlight, direct or indirect ophthalmoscope, retinoscope, or slit lamp. Focal illumination with a penlight held near the eye may reveal an opacity in the lens close to the anterior capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ]. Lens opacities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymmetry of the red reflex may also be noted with a direct ophthalmoscope (with the power at \"0\") at arm's length from the child [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/32\">",
"     32",
"    </a>",
"    ]. The nature and location of a lens opacity is best determined using a slit lamp biomicroscope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Slit lamp examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slit lamp examination can be used to detect a cataract or anterior chamber inflammation. The presence of inflammatory cells and debris in the anterior chamber",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitreous may indicate uveitis or even leukemic infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dilated fundus examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dilated funduscopic examination using the indirect ophthalmoscope is essential in the evaluation of children with leukocoria. However, since an EUA is often required, restraint of the child should be limited during this part of the awake examination. The examination should assess:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Status of the retina (eg, retinal detachment)",
"     </li>",
"     <li>",
"      Presence of retinal vascular abnormalities and or exudate (as may occur in Coats disease)",
"     </li>",
"     <li>",
"      Size, location, and number of tumors, if present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Examination under anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUA is required in children suspected of having retinoblastoma. In addition to examination of the ocular adnexa and anterior segment, both fundi must be visualized for 360 degrees to detect tumors or other pathology that may be located in the peripheral retina. EUA is often required and may facilitate the performance of computed tomography (CT) or magnetic resonance scan, ultrasonography, fundus photography, laboratory and serologic testing, and lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cooperative child, ocular ultrasonography using either one- or two-dimensional display (\"A\" and \"B\" scan, respectively), can help to narrow the differential diagnosis before the EUA. Intraocular pathology, such as regressed retinoblastoma or \"retinoma\", may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Retinoblastoma is likely if calcium is present within the mass and the globe is of normal size [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/14,36-38\">",
"     14,36-38",
"    </a>",
"    ]. Retinoblastoma is exceedingly rare in the presence of cataractous or small eye. PFV is the most likely diagnosis in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/14,39\">",
"     14,39",
"    </a>",
"    ]. Retinal detachment may be present in patients with persistent fetal vasculature (PFV) or Coats disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Persistent fetal vasculature'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children with suspected retinoblastoma require high resolution computed tomography (CT) or magnetic resonance imaging (MRI) of the head and orbits, both for diagnostic confirmation and to exclude a concomitant PNET in the pineal gland (ie, \"trilateral\" retinoblastoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of retinoblastoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation of the child with leukocoria should be directed by the history and physical examination findings, but may include serology or other testing for congenital infections, metabolic studies (eg, for galactosemia), and genetic studies for various syndromes (eg, Turner syndrome). Elevated concentrations of lactate dehydrogenase (LDH) in the aqueous humor are suggestive of retinoblastoma but are not diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5496/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This test is rarely, if ever, performed since the diagnosis of retinoblastoma can almost always be made with the combination of the clinical examination and",
"    <span class=\"nowrap\">",
"     orbital/head",
"    </span>",
"    imaging. In addition, aqueous sampling may increase the risk of extraocular spread of retinoblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children who have been diagnosed with retinoblastoma, the laboratory workup is directed by the selected mode of treatment (eg, baseline complete blood count and chemistries necessary for initiation of chemotherapy). Bone marrow aspiration and lumbar puncture are indicated if extraocular spread is considered possible. Genetic testing, particularly in patients with unilateral retinoblastoma, is recommended to help determine whether the tumor is heritable (for genetic counseling), and whether the patient is at risk for secondary tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of retinoblastoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term leukocoria means \"white pupil\" and is the name given to the clinical finding of a white pupillary reflex (",
"      <a class=\"graphic graphic_picture graphicRef56724 \" href=\"UTD.htm?0/7/124\">",
"       picture 1",
"      </a>",
"      ). Evaluation for leukocoria is part of the routine visual examination performed by the primary care practitioner at health maintenance visits. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with newly discovered leukocoria should promptly be referred to an ophthalmologist to exclude retinoblastoma and other life- or sight-threatening conditions. When possible, this consultation should occur within one week of suspected diagnosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While occasionally the reflection of a normal optic disc, leukocoria can also be caused by abnormalities in the lens, vitreous, or retina. It can be the initial manifestation of a wide spectrum of intraocular and systemic disease processes, and the presenting sign of abusive head trauma. (",
"      <a class=\"graphic graphic_table graphicRef73809 \" href=\"UTD.htm?11/25/11677\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of leukocoria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history for the child with leukocoria should include prenatal exposures (toxins, infection, medications) and complications, birth history, postnatal course (infection, oxygen exposure, medications), medical history, recent exposures (puppies, kittens, pica, geophagia, medications), family history (particularly for retinoblastoma or other eye tumors, eye loss, osteogenic sarcoma, and fetal loss or miscarriage), growth pattern, development, and review of systems. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination of the child with leukocoria should include evaluation for additional signs of the various conditions associated with leukocoria (",
"      <a class=\"graphic graphic_table graphicRef73809 \" href=\"UTD.htm?11/25/11677\">",
"       table 1",
"      </a>",
"      ). Areas that require particular attention include dysmorphic features, growth parameters, signs of coagulopathy or trauma, and organomegaly. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ophthalmic ultrasound is sometimes used to determine the presence or absence of intraocular calcium (indicative of retinoblastoma). Patients with suspected retinoblastoma require further radiologic evaluation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation of the child with leukocoria should be directed by the history and physical examination findings, but may include serology or other testing for congenital infections, metabolic studies (eg, for galactosemia), and genetic studies for various syndromes (eg, Turner syndrome). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/1\">",
"      Simon JW, Kaw P. Commonly missed diagnoses in the childhood eye examination. Am Fam Physician 2001; 64:623.",
"     </a>",
"    </li>",
"    <li>",
"     Mark FP. Pediatarics. In: The Wills Eye Manual, 3rd, Rhee DJ, Pyfer MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.199.",
"    </li>",
"    <li>",
"     Apple DJ, Rabb MF. Ocular pathology: Clinical Applications and Self Assessment, 5th, Mosby, St. Louis 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/4\">",
"      Shields JA, Augsburger JJ. Current approaches to the diagnosis and management of retinoblastoma. Surv Ophthalmol 1981; 25:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/5\">",
"      Kaufman LM, Mafee MF, Song CD. Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd-DTPA contrast enhancement. Radiol Clin North Am 1998; 36:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/6\">",
"      Haik BG, Saint Louis L, Smith ME, et al. Magnetic resonance imaging in the evaluation of leukocoria. Ophthalmology 1985; 92:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/7\">",
"      de Courten C, Faggioni R. Acute infantile leukocoria. Am J Ophthalmol 1990; 109:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/8\">",
"      Butros LJ, Abramson DH, Dunkel IJ. Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences. Pediatrics 2002; 109:E45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/9\">",
"      Cheng KP, Hiles DA, Biglan AW. The differential diagnosis of leukokoria. Pediatr Ann 1990; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/10\">",
"      Howard GM, Ellsworth RM. Differential diagnosis of retinoblastoma. A statistical survey of 500 children. I. Relative frequency of the lesions which simulate retinoblastoma. Am J Ophthalmol 1965; 60:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/11\">",
"      Devesa SS. The incidence of retinoblastoma. Am J Ophthalmol 1975; 80:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/12\">",
"      Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990; 108:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/13\">",
"      Rubenfeld M, Abramson DH, Ellsworth RM, Kitchin FD. Unilateral vs. bilateral retinoblastoma. Correlations between age at diagnosis and stage of ocular disease. Ophthalmology 1986; 93:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/14\">",
"      Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     The eyes. In: Pediatric diagnosis: Interpretation of symptoms and signs in children and adolescents, 6th, Green M (Ed), WB Saunders Company, Philadelphia 1998. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/16\">",
"      Haddad R, Font RL, Reeser F. Persistent hyperplastic primary vitreous. A clinicopathologic study of 62 cases and review of the literature. Surv Ophthalmol 1978; 23:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/17\">",
"      Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. a multivariate statistical analysis. Ophthalmologica 2000; 214:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/18\">",
"      Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/19\">",
"      Giles CL. Pediatric intermediate uveitis. J Pediatr Ophthalmol Strabismus 1989; 26:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/20\">",
"      Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol 2001; 131:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/21\">",
"      Smithen LM, Brown GC, Brucker AJ, et al. Coats' disease diagnosed in adulthood. Ophthalmology 2005; 112:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/22\">",
"      Black GC, Perveen R, Bonshek R, et al. Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 1999; 8:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/23\">",
"      Kincaid MC, Green WR. Ocular and orbital involvement in leukemia. Surv Ophthalmol 1983; 27:211.",
"     </a>",
"    </li>",
"    <li>",
"     Traboulsi EI. Pediatric ophthalmology. In: Oski's Pediatrics. Principles and Practice, 4th, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.801.",
"    </li>",
"    <li>",
"     Norrie disease. In: Online Mendelian Inheritance in Man, Johns Hopkins University, Baltimore, MD. file://omim.org/entry/310600?search=norrie%20disease&amp;highlight=norrie%20disease (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/26\">",
"      Canzano JC, Handa JT. Utility of pupillary dilation for detecting leukocoria in patients with retinoblastoma. Pediatrics 1999; 104:e44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/27\">",
"      Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/28\">",
"      DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 1988; 41:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/29\">",
"      MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. Arch Ophthalmol 1984; 102:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/30\">",
"      Kingston JE, Clark J, Santos H, et al. Failure to thrive leading to early detection of retinoblastoma. Pediatr Hematol Oncol 1990; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/31\">",
"      Holladay DA, Holladay A, Montebello JF, Redmond KP. Clinical presentation, treatment, and outcome of trilateral retinoblastoma. Cancer 1991; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/32\">",
"      American Academy of Pediatrics, Section on Ophthalmology, American Association for Pediatric Ophthalmology And Strabismus, et al. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/33\">",
"      Pierro L, Brancato R, Capoferri C. Prenatal detection and early diagnosis of hereditary retinoblastoma in a family. Ophthalmologica 1993; 207:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/34\">",
"      Onadim Z, Hykin PG, Hungerford JL, Cowell JK. Genetic counselling in retinoblastoma: importance of ocular fundus examination of first degree relatives and linkage analysis. Br J Ophthalmol 1991; 75:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/35\">",
"      Atta HR, Watson NJ. Echographic diagnosis of advanced Coats' disease. Eye (Lond) 1992; 6 ( Pt 1):80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/36\">",
"      Mafee MF, Goldberg MF, Cohen SB, et al. Magnetic resonance imaging versus computed tomography of leukocoric eyes and use of in vitro proton magnetic resonance spectroscopy of retinoblastoma. Ophthalmology 1989; 96:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/37\">",
"      Char DH, Hedges TR 3rd, Norman D. Retinoblastoma. CT diagnosis. Ophthalmology 1984; 91:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/38\">",
"      Malkani I, Warrier RP, Yu LC, Ode DL. Retinoblastoma: a review. Indian J Pediatr 1993; 60:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/39\">",
"      Mackeen LD, Nischal KK, Lam WC, Levin AV. High-frequency ultrasonography findings in persistent hyperplastic primary vitreous. J AAPOS 2000; 4:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/40\">",
"      Piro PA Jr, Abramson DH, Ellsworth RM, Kitchin D. Aqueous humor lactate dehydrogenase in retinoblastoma patients. Clinicopathologic correlations. Arch Ophthalmol 1978; 96:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5496/abstract/41\">",
"      Lifshitz T, Tessler Z, Maor E, Yassur Y. Increased aqueous lactic dehydrogenase in Coat's disease. Ann Ophthalmol 1987; 19:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6259 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5496=[""].join("\n");
var outline_f5_23_5496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF LEUKOCORIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Persistent fetal vasculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Optic disc abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Toxocariasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coats disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vitreous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Retinal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OPHTHALMOLOGIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      External examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Muscle balance and alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pupils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dilated fundus examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Examination under anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6259|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/3/38962\" title=\"diagnostic image 1\">",
"      Coats disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32506\" title=\"figure 1\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/15/42239\" title=\"figure 2\">",
"      Afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6259|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/7/124\" title=\"picture 1\">",
"      Leukocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/47/43761\" title=\"picture 2\">",
"      Retinoblastoma gross path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/26/21922\" title=\"picture 3\">",
"      Persist fetal vasculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/27/1457\" title=\"picture 4\">",
"      Optic nerve coloboma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/31/40433\" title=\"picture 5\">",
"      Morning glory disc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/55/10096\" title=\"picture 6\">",
"      Myelinated nerve fibers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/1/8210\" title=\"picture 7\">",
"      Optic disc infiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/47/16113\" title=\"picture 8\">",
"      Toxocariasis eye findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/25/11677\" title=\"table 1\">",
"      DDx Leukocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15037\" title=\"table 2\">",
"      Vision screen infants children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=related_link\">",
"      Toxocariasis: visceral and ocular larva migrans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5497="Left ventricular thrombus after acute myocardial infarction";
var content_f5_23_5497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left ventricular thrombus after acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Neil J Weissman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Scott Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5497/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/23/5497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) thrombus is one of the more common complications of myocardial infarction (MI). Thrombus development is important because it can lead to arterial embolic complications such as stroke. Patients with LV thrombus, or those at high risk, should receive anticoagulation for at least three months.",
"   </p>",
"   <p>",
"    This topic will focus on the diagnosis of LV thrombus and the prevention of embolic complications. Other complications of MI such as arrhythmias, cardiogenic shock, and mechanical complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link\">",
"     \"Supraventricular arrhythmias after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of arterial emboli are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Arterial emboli'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141352237\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83344408\">",
"    <span class=\"h2\">",
"     Formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing a LV thrombus after an acute MI varies with infarct location and size. LV thrombus is most often seen in patients with large anterior ST-elevation infarctions (STEMI) with anteroapical aneurysm formation; the incidence is lower with smaller infarctions and those involving other myocardial regions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1-11\">",
"     1-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These anterior infarcts have large areas of poorly contracting left ventricular muscle; adjacent intracavitary blood movement is sluggish compared to normal areas. This relative stasis of blood is thought to increase the risk of thrombus formation. An LV aneurysm and a mural thrombus have been identified in autopsy or surgery in more than 50 percent of these patients. Two factors contribute to clot formation in this setting: stasis of flow in the aneurysm cavity and contact of blood with the fibrous tissue in the aneurysm rather than normal endocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=see_link&amp;anchor=H9#H9\">",
"     \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\", section on 'Systemic embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One way to assess infarct size is to measure the left ventricular ejection fraction (LVEF). Among patients in the GISSI-3 database, for example, an LVEF &le;40 percent was associated with an increase in the incidence of LV thrombus with both anterior MI (17.8 versus 9.6 percent with a higher LVEF) and infarctions at other sites (5.4 versus 1.8 percent). Overall, anterior infarction is associated with a lower LVEF than infarctions elsewhere in the LV.",
"   </p>",
"   <p>",
"    The incidence of LV thrombi in the pre-reperfusion era was reported to be as high as 40 percent in patients with anterior infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Most thrombi developed within the first two weeks (median five to six days) after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/2,3,6,9,10\">",
"     2,3,6,9,10",
"    </a>",
"    ]. In a series of 30 patients with LV thrombus after an acute anterior MI, 27 percent were present at less than 24 hours, 57 percent at 48 to 72 hours, 75 percent at one week, and 96 percent at two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of LV thrombus in patients treated with fibrinolytic therapy was studied in 8326 individuals in the GISSI-3 database; a predischarge transthoracic echocardiogram (TTE) was performed a mean of nine days after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/8\">",
"     8",
"    </a>",
"    ]. LV thrombus was present in 5.1 percent of patients overall: 11.5 percent of those with an anterior wall infarction and 2.3 percent of those with infarctions at other sites. The possible role of fibrinolytic therapy in preventing LV thrombus is discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prevention of formation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data are more limited on the incidence of LV thrombus after primary percutaneous coronary intervention for STEMI. In two series with a combined total of 163 patients in whom TTE was performed at two to three days and within five days, respectively, LV thrombus was detected in seven patients (4.3 percent) and only in those with anterior MI (10.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These findings are similar to those seen with fibrinolytic therapy in GISSI-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/8\">",
"     8",
"    </a>",
"    ] and support a decreased incidence of LV thrombus since the widespread use of reperfusion.",
"   </p>",
"   <p>",
"    In the studies of incidence reported above, the diagnosis of LV thrombus was made using TTE. The reported incidences may underestimate the true incidence, since more series have shown significantly higher rates of LV thrombi identified with cardiovascular magnetic resonance (CMR) imaging compared to both TTE and transesophageal echocardiography. In addition, some of these studies may have underestimated the true incidence, as patients at high risk for LV thrombus (severe heart failure and systolic blood pressure below 100 mmHg) were excluded. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cardiovascular magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83344358\">",
"    <span class=\"h2\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of embolization in patients with a documented LV thrombus who are not treated with anticoagulant therapy has been reported to be between 10 and 15 percent. In a series of 85 patients with LV thrombus (most of whom had a recent MI) who were followed for almost two years, an embolic event occurred in 11 (13 percent) of those with thrombi compared to only 2 of 91 (2 percent) in a matched control group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/14\">",
"     14",
"    </a>",
"    ]. A 1993 meta-analysis included 11 studies of 856 patients who had had an anterior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/15\">",
"     15",
"    </a>",
"    ]. The odds ratio for an embolic event was 5.5 (95% CI 3.0-9.8) comparing those with to those without an LV mural thrombus documented on echocardiography. Most embolic events occur within the first three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1,4,5,14-17\">",
"     1,4,5,14-17",
"    </a>",
"    ], although some occur later [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transthoracic echocardiography (TTE) can help identify those patients at high risk of thromboembolism. Two major risk factors have been identified: mobile thrombus and protruding thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1,5,14,18\">",
"     1,5,14,18",
"    </a>",
"    ]. In one report, embolization occurred in 26 of 119 patients with an LV thrombus after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1\">",
"     1",
"    </a>",
"    ]. Free mobility of the thrombus was present in 58 percent of patients with embolization compared to 3 percent without embolization; among the 18 patients with free thrombus mobility, embolization occurred in 15 (83 percent compared to 11 percent without mobility). Protrusion of the thrombus into the LV cavity was present in 88 percent of those patients with emboli compared to 18 percent without; among the 40 patients with thrombus protrusion, embolization occurred in 23 (58 percent compared to 4 percent without protrusion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend transthoracic echocardiography (TTE) for all patients at high risk of LV thrombus. High-risk patients are identified by either the presence of an anterior ST-elevation MI on the electrocardiogram (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link&amp;anchor=H9#H9\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\", section on 'Anterior and apical MI'",
"    </a>",
"    ), the presence of a severe anteroapical wall motion abnormality on an imaging study (eg, left ventriculography with contrast or radionuclide ventriculography), or occlusion of the left anterior descending artery on coronary arteriography. The TTE can secure the diagnosis of LV thrombus; it can also help identify patients without thrombus, but who are at high risk, who might benefit from anticoagulation. (See",
"    <a class=\"local\" href=\"#H16390947\">",
"     'Prevention of embolic events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive accuracy of TTE was illustrated in a study that evaluated 78 patients who underwent non-contrast TTE and had independent proof (by autopsy, surgery, or scintigraphy) of the presence (22 patients) or absence of LV thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/19\">",
"     19",
"    </a>",
"    ]. TTE was positive in 22, equivocal in seven, and negative in 49. The overall sensitivity and specificity were 95 and 86 percent, respectively. The predictive value of a positive study was 86 percent compared to only 29 percent (two of seven) with an equivocal study.",
"   </p>",
"   <p>",
"    The sensitivity of TTE for the detection of LV thrombus may be suboptimal due to poor image quality (chronic pulmonary disease or obesity) and the difficulty in distinguishing thrombus from normal trabeculations. In patients in whom suboptimal acoustic windows or prominent LV apical muscle bands and trabeculations confound the recognition of thrombus, many experts recommend use of an intravenous contrast agent to opacify the LV apex to improve the sensitivity and specificity of thrombus detection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. LV thrombi appear as a filling defect separated from the myocardium by contrast, while muscular structures or spontaneous echo contrast (smoke) are obscured.",
"   </p>",
"   <p>",
"    Cardiovascular magnetic resonance (CMR) imaging should be considered when the quality of the TTE is suboptimal and the patient is felt to be at high risk (eg, apical aneurysm or large anterior MI) for the development of LV thrombus, but would not otherwise receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (eg, because of increased bleeding risk). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cardiovascular magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2011",
"    <span class=\"nowrap\">",
"     ACC/AHA/ASE",
"    </span>",
"    task force gave an &ldquo;appropriate&rdquo; recommendation to the use of TTE for the assessment of mural thrombus after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/22\">",
"     22",
"    </a>",
"    ]. We suggest performing a TTE as soon as an at-risk patient is identified. This includes patients who are suspected of having a large anterior MI based on clinical and electrocardiographic criteria. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22205932\">",
"    <span class=\"h3\">",
"     Thrombus appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TTE appearance of LV thrombus is variable, and depends upon its age (",
"    <a class=\"graphic graphic_movie graphicRef85959 \" href=\"UTD.htm?34/40/35460\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef85958 \" href=\"UTD.htm?6/53/6995\">",
"     movie 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fresh thrombus tends to protrude into the center of the ventricular cavity and is highly mobile. Thrombus is often difficult to differentiate from the \"pseudo-contrast\" effect of slowly moving cavitary blood seen within left ventricular aneurysms.",
"     </li>",
"     <li>",
"      Thrombus formed recently tends to protrude to the center of the chamber. The intracavitary surface can be highly reflective or luminescent in appearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older thrombus generally has a smooth cavitary surface and a texture resembling the ultrasound appearance of hepatic tissue. It is less likely to change or embolize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR appears to have a greater sensitivity than TTE and a similarly high specificity for the detection of chronic LV thrombus in an ischemic cardiomyopathy population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 160 patients with a remote prior MI who had surgical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathological confirmation of the presence (48 patients [30 percent]) or absence of LV thrombus, all patients underwent preoperative CMR with late gadolinium enhancement, TTE, and intraoperative transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/23\">",
"     23",
"    </a>",
"    ]. CMR was significantly more sensitive (88 versus 23 and 40 percent with TTE and transesophageal echocardiography, respectively). All imaging modalities had specificities of 96 percent or greater.",
"   </p>",
"   <p>",
"    Increased sensitivity was also noted in an analysis of 57 patients with acute or past MI or ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/24\">",
"     24",
"    </a>",
"    ]. Late gadolinium enhancement CMR detected mural LV thrombus in 12 (21 percent); only five were seen by TTE. The thrombi not seen on TTE were primarily located at the LV apex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16390947\">",
"    <span class=\"h1\">",
"     PREVENTION OF EMBOLIC EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy should be started early and continued for three to four months after MI to lower the risk embolization of LV thrombus in patients at risk. At risk patients include those with documented LV thrombus on TTE or at high risk by having an LVEF less than 40 percent and an antero-apical wall motion abnormality or aneurysm on imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion and parenteral anticoagulant therapies lower the risk of thrombus formation. While it has not been directly proven, it is assumed that the prevention of thrombus formation lowers the risk of thrombus embolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108369761\">",
"    <span class=\"h3\">",
"     Reperfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reperfusion therapy with fibrinolysis or percutaneous coronary intervention (PCI) is indicated in many patients with acute myocardial infarction to improve mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H2#H2\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'General issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Benefit and timing of early intervention'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The following evidence supports the concept that reperfusion therapy lowers the risk of thrombus formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 11.5 percent incidence of LV thrombi in patients with acute anterior MI treated with fibrinolytic therapy in the GISSI-3 database [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/8\">",
"       8",
"      </a>",
"      ] and the 4 to 17 percent incidence in other series in the reperfusion era (fibrinolysis or PCI) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/9,10,12,13\">",
"       9,10,12,13",
"      </a>",
"      ] is lower than the 20 to 40 percent incidence noted in smaller studies from the pre-fibrinolytic era [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1-5,26\">",
"       1-5,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 1993 meta-analysis of six trials including 390 patients who had had an anterior MI, the odds ratio of LV thrombus with fibrinolytic compared to no fibrinolytic therapy was 0.48 (95% CI 0.29-0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reperfusion therapy is thought to reduce the incidence of LV thrombus by limiting infarct size. Its impact may be greatest in patients with anterior infarctions, which tend to be larger than infarcts at other locations. (See",
"    <a class=\"local\" href=\"#H83344408\">",
"     'Formation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108369768\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , if started early and continued for more than 48 hours, lowers the risk of thrombus formation.",
"   </p>",
"   <p>",
"    A 1993 meta-analysis found that short-term (up to 48 hours)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lowered the rate of thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/15\">",
"     15",
"    </a>",
"    ]. A much larger study of 8326 patients from the GISSI-3 database found no significant difference in the incidence of thrombus formation in patients who did and did not receive short-term heparin, but an analysis attempting to control for confounders was not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the inconsistent conclusions in the studies of short-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, randomized trials have provided some evidence that more prolonged therapy with unfractionated or low molecular weight heparin reduces the short-term risk of the development of LV thrombus in patients with an acute anterior STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a dose comparison trial, 221 patients with acute, anterior MI were randomly assigned to high (12,500 units) or low (5000 units) dose subcutaneous unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      given every 12 hours for 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/26\">",
"       26",
"      </a>",
"      ]. High dose therapy was associated with a significantly lower incidence of LV thrombus (11 versus 32 percent).",
"     </li>",
"     <li>",
"      In the FRAMI trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      , a low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , 776 patients with an acute anterior STEMI treated with streptokinase and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      were randomly assigned to drug or placebo for nine days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/27\">",
"       27",
"      </a>",
"      ]. Dalteparin significantly reduced the incidence of LV thrombus (14 versus 22 percent) at the cost of an increased incidence of major bleeding (2.9 versus 0.3 percent). There was no difference between the groups in the risk of embolization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a separate issue, the effect of parenteral anticoagulation on thrombus size and features was evaluated in an observational study of 23 patients with LV thrombus and the high-risk TTE features of mobile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protruding thrombi who were treated with a high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    infusion for a mean of 14 days (range 7 to 22 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients showed both a decrease in the size of the thrombus and thrombus disappeared in 19. In addition, the high-risk TTE features disappeared in all patients. (See",
"    <a class=\"local\" href=\"#H83344358\">",
"     'Embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We believe these studies support the concept that early and continuous effective anticoagulation reduces the risk of LV thrombus formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16390532\">",
"    <span class=\"h2\">",
"     Prevention of embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    lowers the risk of thrombus embolization. In the absence of anticoagulation, the risk of embolization in patients with a documented LV thrombus has been reported to be between 10 and 15 percent. Most events occur within the first three to four months; this observation forms the basis for our recommendations regarding the duration of anticoagulant therapy.",
"   </p>",
"   <p>",
"    There are no randomized trials evaluating the efficacy of anticoagulation to prevent embolization in patients with an LV thrombus after MI. Nevertheless, observational studies provide support for a recommendation to anticoagulate patients with documented LV thrombus after MI to reduce the risk of embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/6,15-17\">",
"     6,15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 43 patients with LV thrombus after MI who were followed for a mean of 15 months, there were no embolic events in the 25 patients treated with anticoagulation; in comparison, 7 of 18 untreated patients had an embolic event, all occurring within four months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of seven observational studies that included 270 patients with anterior MI and echocardiographically documented LV thrombus, anticoagulation (compared to no anticoagulation) was associated with an 86 percent reduction in the rate of embolization (odds ratio 0.14, 95% CI 0.04-0.52) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above studies demonstrate a benefit from anticoagulation in patients with LV thrombus. We believe that such therapy will also be of benefit to those at high risk, defined as those with an LVEF less than 30 percent or a severe antero-apical wall motion abnormality with apical aneurysm on an imaging study. Similar patients with an LVEF between 30 and 40 percent may also benefit, but the benefit to (bleeding) risk ratio declines.",
"   </p>",
"   <p>",
"    There are no data on the use of oral thrombin inhibitors or factor Xa inhibitors in this setting.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy reduces the incidence of embolization, it may not promote thrombus resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/6\">",
"     6",
"    </a>",
"    ]. Other factors that might contribute to the warfarin benefit are prevention of thrombus extension and the promotion of endothelialization of the thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141352998\">",
"    <span class=\"h3\">",
"     Role of dual antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies presented in the section above were performed before the routine use of dual antiplatelet therapy (DAT) in patients with acute MI, and in particular those who undergo PCI with stenting. While it is biologically plausible that DAT could protect against the formation and embolization of LV thrombus, this has not been studied. Our recommendations for the use of antiplatelet therapy in patients with acute coronary syndromes are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H185089155#H185089155\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'All patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute anterior MI who are at high risk for the development of LV thrombus (LVEF less than 40 percent and a severe antero-apical wall motion abnormality on imaging) are candidates for both DAT and anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/30\">",
"     30",
"    </a>",
"    ]. This triple antithrombotic therapy, if used, places patients at high risk for a bleeding complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H7#H7\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triple antithrombotic therapy has not been directly compared to DAT in MI patients at risk for LV thrombus. In the 2012 American College of Chest Physicians (ACCP) guidelines on Antithrombotic Therapy and Prevention of Thrombosis guidelines, which include a document on &ldquo;Primary and Secondary Prevention of Cardiovascular Disease&rdquo;, the authors used indirect evidence to compare expected outcomes between triple antithrombotic therapy or dual antiplatelet therapy in patients with acute, large anterior MI at risk for or with LV thrombus who undergo PCI with stent placement (either bare-metal or drug-eluting) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/30\">",
"     30",
"    </a>",
"    ]. The anticipated effects over three months (comparing triple therapy to dual antiplatelet therapy) included no effect on total mortality, a decrease in nonfatal MI (relative risk [RR] 0.69, 95% CI 0.54-0.88), a decrease in all strokes (RR 0.0.56, 95% CI 0.39-0.82), and an increase in major extracranial bleeds (RR 2.37, 95% CI 1.62-3.47).",
"   </p>",
"   <p>",
"    Triple antithrombotic therapy has not been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    plus one antiplatelet agent in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16390955\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence presented in the sections above on prevention of thrombus formation and thrombus embolization suggests that if anticoagulation is started at the moment an at-risk patient is identified and continued for several months after initiation, the risks of thrombus formation and systemic embolization are lowered. Patients with an LV thrombus identified after MI (at any location) or those with anterior MI and an LVEF less than 30 percent are at particularly high risk of systemic embolization. Patients with an LVEF between 30 and 40 percent are also at risk, but the level of risk is not as great. Anticoagulation is also reasonable in these patients, particularly if the risk of bleeding is not high.",
"   </p>",
"   <p>",
"    We believe that most patients with LV thrombus and those at high risk should receive anticoagulant therapy for three months after acute MI based in part on the observation that most events occur during this time frame. Some experts prescribe anticoagulant therapy for as long as four months. (See",
"    <a class=\"local\" href=\"#H83344358\">",
"     'Embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All decisions regarding the prolonged use of anticoagulant therapy in these patients must take into account the concurrent risk of bleeding. Bleeding is a particularly important issue as many of these patients will need to be on triple antithrombotic therapy due to the placement of an intracoronary stent or as secondary prevention after an acute coronary syndrome. (See",
"    <a class=\"local\" href=\"#H141352998\">",
"     'Role of dual antiplatelet therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The choice of three months of anticoagulation is based on the recognition that the rate of embolization in untreated patients begins to decline at this time, while the rate of major bleeding with multiple antithrombotic agents is nearly constant.",
"   </p>",
"   <p>",
"    Although there are no studies that have evaluated the optimal timing of parenteral anticoagulation in patients being started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , we believe it is reasonable to start therapy as soon as an at-risk patient is identified and to discontinue parenteral therapy when effective anticoagulation with warfarin has been achieved (international normalized ratio [INR] of 2.0 to 3.0).",
"   </p>",
"   <p>",
"    For the most part, we agree with recommendations made in the 2012 American College of Chest Physicians (ACCP) guidelines on Antithrombotic Therapy and Prevention of Thrombosis guidelines, which include a document on &ldquo;Primary and Secondary Prevention of Cardiovascular Disease&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/30\">",
"     30",
"    </a>",
"    ]. This document specifies that at-risk patients include those with anterior MI and LV thrombus; we believe that any LV thrombus consequent to MI, irrespective of location, should be treated.",
"   </p>",
"   <p>",
"    The following recommendations, which have been adapted from the ACCP guideline, apply to patients with acute MI and LV thrombus on imaging study or those at high risk (LVEF &lt;30 percent and a severe antero-apical wall motion abnormality):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend starting parenteral anticoagulation with unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or a low molecular weight heparin as soon as an at-risk patient is identified. The goal aPTT is 2 to 3 times the mean of the control value. Parenteral anticoagulation should be continued until effective anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      has been achieved.",
"     </li>",
"     <li>",
"      We recommend starting oral anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (in addition to antiplatelet therapy) soon after initiation of parenteral anticoagulation. Any delay may unnecessarily prolong the duration of hospitalization. The goal international normalized ratio is 2.0 to 3.0.",
"      <br/>",
"      <br/>",
"      The duration of warfarin is determined by whether an intracoronary stent has been placed and by the type of stent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who did not undergo percutaneous coronary intervention (PCI), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily for three months, as opposed to single or dual antiplatelet therapy. Although there is some rationale for the use of triple antithrombotic therapy for three months given the presence of both a recent acute coronary syndrome and the potential for LV thrombus, we do not recommend its use. We feel the risk of bleeding exceeds the benefit of the prevention of recurrent ischemic events or thromboembolism.",
"     </li>",
"     <li>",
"      For patients who undergo PCI with a bare-metal stent placed, we suggest triple antithrombotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily for one month, as compared to any other antithrombotic regimen. During months two and three, we suggest warfarin and a single antiplatelet agent, as compared to any other antithrombotic regimen or any other duration. Although there is some rationale for the use of triple antithrombotic therapy for three months given the presence of both a recent ACS and the potential for LV thrombus, we do not recommend its use. We feel the risk of bleeding exceeds the benefit or the prevention of recurrent ischemic events or thromboembolism.",
"     </li>",
"     <li>",
"      For patients who have a PCI with a drug-eluting stent placed, we suggest triple antithrombotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily for three months as compared to any other antithrombotic regimen. This recommendation differs from that found in the ACCP guideline, as they recommend therapy for three to six months for these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After termination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      we recommend dual antiplatelet therapy with low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100 mg daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75 mg daily) for up to one year. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H169940279#H169940279\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'No reperfusion therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present there is no defined role for oral thrombin inhibitors or factor Xa inhibitors as a substitute for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16390357\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, we agree for the most part with recommendations made in the 2012 American College of Chest Physicians guidelines on Antithrombotic Therapy and Prevention of Thrombosis guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/30\">",
"     30",
"    </a>",
"    ]. Similar recommendations were made in the 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and the 2006 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association guidelines on the prevention of ischemic stroke (updated in 2011) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22205751\">",
"    <span class=\"h2\">",
"     Role of follow-up echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic echocardiography (TTE) can be used to monitor resolution of thrombus with anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/1,3,5,6,11\">",
"     1,3,5,6,11",
"    </a>",
"    ]. In summing three series in which serial TTE was performed, thrombus resolution was seen in 14 of 29 patients (47 percent) at six months, 24 of 51 (47 percent) at one year, 16 of 21 (76 percent) at two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/3,5,11\">",
"     3,5,11",
"    </a>",
"    ]. As noted below, only a small number of late persistent thrombi are associated with embolic events as most embolic events occur within the first four months. (See",
"    <a class=\"local\" href=\"#H16390532\">",
"     'Prevention of embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The predictors of LV thrombus resolution are not well defined. In one report, the only independent predictor of thrombus resolution was the absence of apical dyskinesis at six weeks after the infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/11\">",
"     11",
"    </a>",
"    ]. This observation is consistent with apical dyskinesis or akinesis being a risk factor for thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/2\">",
"     2",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy appears to reduce the rate of embolization, it may not increase the rate of thrombus resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5497/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on a limited amount of evidence, we believe it is reasonable to get a follow-up TTE to either see if the thrombus&nbsp;identified&nbsp;on the first TTE has resolved or organized or to assess the degree of LV remodeling. The findings of persistent pedunculation of the thrombus may reasonably lead to a decision to prolong anticoagulation beyond the recommended time; the finding of significant improvement of the LVEF and apical wall motion abnormality may reasonably lead to a decision to shorten the duration of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459652175\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) thrombus is a major cause of embolic stroke after acute myocardial infarction (MI). Patients with large anterior MI are at the highest risk for the development of LV thrombi; these patients usually have an LV ejection fraction less than 40 percent and a severe antero-apical wall motion abnormality on an imaging study. (See",
"    <a class=\"local\" href=\"#H83344408\">",
"     'Formation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients at risk of LV thrombus due to a large or anterior MI based on clinical and electrocardiographic information, we recommend a transthoracic echocardiogram (TTE) to screen for LV thrombus. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most at risk patients should be treated with anticoagulant therapy to prevent embolization of thrombi. However, as anticoagulant therapy is usually coupled with antiplatelet therapy, the risk of major bleeding must be weighed against this benefit in all patients. (See",
"    <a class=\"local\" href=\"#H141352998\">",
"     'Role of dual antiplatelet therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations are as follows (see",
"    <a class=\"local\" href=\"#H16390955\">",
"     'Our approach'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with MI and documented LV thrombus or those at high risk (LV ejection fraction less than 30 percent and a severe antero-apical wall motion abnormality on imaging), we recommend immediate anticoagulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients with MI and an LV ejection fraction between 30 and 40 percent and a severe antero-apical wall motion abnormality on imaging, we suggest immediate anticoagulation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The relative benefits and risks of anticoagulation need to be weighed carefully in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    Parenteral anticoagulation with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin should be started as soon as an at-risk patient is identified and continued until effective anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has been achieved. (See",
"    <a class=\"local\" href=\"#H108369768\">",
"     'Heparin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      should be started soon after initiation of parenteral anticoagulation; the goal of therapy is an international normalized ratio (INR) of 2.0 to 3.0. The duration of warfarin is determined by whether an intracoronary stent has been placed and by the type of stent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who did not undergo coronary artery stenting, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily for three months, as opposed to single or dual antiplatelet therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who had bare-metal stents placed, we suggest triple antithrombotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily for one month, as compared to dual antiplatelet therapy",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). During months two and three, we suggest warfarin and a single antiplatelet agent, as compared to other antithrombotic regimens and other durations of warfarin",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who had drug-eluting stents placed, we suggest triple antithrombotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily for three months as",
"      <strong>",
"      </strong>",
"      compared to other antithrombotic regimens and other durations of warfarin",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      After termination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      in the three groups of patients above, dual antiplatelet therapy should be used according to recommendations for patients with recent acute MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H185089155#H185089155\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'All patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/1\">",
"      Visser CA, Kan G, Meltzer RS, et al. Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients. J Am Coll Cardiol 1985; 5:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/2\">",
"      Asinger RW, Mikell FL, Elsperger J, Hodges M. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography. N Engl J Med 1981; 305:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/3\">",
"      Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity. J Am Coll Cardiol 1989; 14:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/4\">",
"      K&uuml;pper AJ, Verheugt FW, Peels CH, et al. Left ventricular thrombus incidence and behavior studied by serial two-dimensional echocardiography in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism and oral anticoagulation. J Am Coll Cardiol 1989; 13:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/5\">",
"      Keren A, Goldberg S, Gottlieb S, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol 1990; 15:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/6\">",
"      Weinreich DJ, Burke JF, Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med 1984; 100:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/7\">",
"      Vecchio C, Chiarella F, Lupi G, et al. Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study. Circulation 1991; 84:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/8\">",
"      Chiarella F, Santoro E, Domenicucci S, et al. Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 1998; 81:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/9\">",
"      Greaves SC, Zhi G, Lee RT, et al. Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Am J Cardiol 1997; 80:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/10\">",
"      Nayak D, Aronow WS, Sukhija R, et al. Comparison of frequency of left ventricular thrombi in patients with anterior wall versus non-anterior wall acute myocardial infarction treated with antithrombotic and antiplatelet therapy with or without coronary revascularization. Am J Cardiol 2004; 93:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/11\">",
"      Neskovi AN, Marinkovi J, Boji M, Popovi AD. Predictors of left ventricular thrombus formation and disappearance after anterior wall myocardial infarction. Eur Heart J 1998; 19:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/12\">",
"      Rehan A, Kanwar M, Rosman H, et al. Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors. A prospective observational study. Cardiovasc Ultrasound 2006; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/13\">",
"      Kalra A, Jang IK. Prevalence of early left ventricular thrombus after primary coronary intervention for acute myocardial infarction. J Thromb Thrombolysis 2000; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/14\">",
"      Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/15\">",
"      Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993; 22:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/16\">",
"      Keating EC, Gross SA, Schlamowitz RA, et al. Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography. Am J Med 1983; 74:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/17\">",
"      Cregler LL. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 1992; 123:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/18\">",
"      Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med 1986; 104:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/19\">",
"      Stratton JR, Lighty GW Jr, Pearlman AS, Ritchie JL. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation 1982; 66:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/20\">",
"      Mansencal N, Nasr IA, Pilli&egrave;re R, et al. Usefulness of contrast echocardiography for assessment of left ventricular thrombus after acute myocardial infarction. Am J Cardiol 2007; 99:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/21\">",
"      Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009; 2:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/22\">",
"      American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011; 57:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/23\">",
"      Srichai MB, Junor C, Rodriguez LL, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 2006; 152:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/24\">",
"      Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002; 106:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/25\">",
"      Barkhausen J, Hunold P, Eggebrecht H, et al. Detection and characterization of intracardiac thrombi on MR imaging. AJR Am J Roentgenol 2002; 179:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/26\">",
"      Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/27\">",
"      Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997; 30:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/28\">",
"      Nordrehaug JE, Johannessen KA, von der Lippe G. Usefulness of high-dose anticoagulants in preventing left ventricular thrombus in acute myocardial infarction. Am J Cardiol 1985; 55:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/29\">",
"      Heik SC, Kupper W, Hamm C, et al. Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk. J Am Coll Cardiol 1994; 24:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/30\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/31\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/32\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5497/abstract/33\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 90 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5497=[""].join("\n");
var outline_f5_23_5497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H459652175\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141352237\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83344408\">",
"      Formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83344358\">",
"      Embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22205932\">",
"      - Thrombus appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16390947\">",
"      PREVENTION OF EMBOLIC EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108369761\">",
"      - Reperfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108369768\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16390532\">",
"      Prevention of embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H141352998\">",
"      - Role of dual antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16390955\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16390357\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22205751\">",
"      Role of follow-up echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459652175\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/90\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/90|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/40/35460\" title=\"movie 1\">",
"      Left ventricular apical thrombus with contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/53/6995\" title=\"movie 2\">",
"      Left ventricular apical thrombus without contrast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5498="Small cell neuroendocrine carcinoma of the cervix";
var content_f5_23_5498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Small cell neuroendocrine carcinoma of the cervix",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Mario M Leitao, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Oliver Zivanovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/23/5498/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/23/5498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1336437714\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer encompasses several histologic types, of which the most common is squamous cell (70 percent) (",
"    <a class=\"graphic graphic_table graphicRef65824 \" href=\"UTD.htm?2/38/2668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Adenocarcinoma and its variants account for about 25 percent of cases, while other histologic subtypes are uncommon. Cervical neuroendocrine (mainly small cell) tumors represent only about 2 percent of all cervical malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1997, a workshop sponsored by the College of American Pathologists and the National Cancer Institute proposed standardized terminology for neuroendocrine tumors of the uterine cervix that was created as a parallel to those used for pulmonary neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"     \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four categories were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small cell neuroendocrine carcinoma",
"     </li>",
"     <li>",
"      Large cell neuroendocrine carcinoma",
"     </li>",
"     <li>",
"      Typical carcinoid tumor",
"     </li>",
"     <li>",
"      Atypical carcinoid tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small cell neuroendocrine carcinoma, first described in 1957, is the most common neuroendocrine tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/8\">",
"     8",
"    </a>",
"    ]. The less common large cell variant, although histologically distinct, shares the same natural history and is treated similarly. The least common type of neuroendocrine cancer that arises in the cervix, a well-differentiated carcinoid tumor, exhibits the typical carcinoid features seen elsewhere in the body (non-existent or minimal cytologic atypia, rare or no mitotic figures, no necrosis), has a different natural history and treatment, and is not discussed further in this review.",
"   </p>",
"   <p>",
"    The natural history of small cell neuroendocrine carcinoma is significantly worse than that of the more common squamous cell cancer or adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Small cell neuroendocrine carcinomas are more likely to have lymph node metastases and lymphovascular space invasion, and their clinical course is marked by early hematogenous dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/6,11-13\">",
"     6,11-13",
"    </a>",
"    ]. Small cell neuroendocrine carcinoma represents an extrapulmonary variant of small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"     \"Neuroendocrine cancer of unknown primary site\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like small cell lung cancer (and its large cell variant), the outcome of small cell neuroendocrine carcinoma of the cervix is associated with disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/14-18\">",
"     14-18",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Staging'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited-stage disease, which by definition, can be encompassed within a single radiotherapy port, is generally treated with combined modality therapy; five-year survival rates are approximately 30 percent.",
"     </li>",
"     <li>",
"      Extensive-stage disease (defined as disease outside of these confines) is treated with chemotherapy alone and associated with a dismal prognosis; there are few, if any, survivors beyond two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will cover the epidemiology, clinical presentation, staging, and treatment of small cell neuroendocrine carcinoma of the cervix. Management of squamous cell cervical cancer and adenocarcinoma arising in the uterine cervix, as well as management of other extrapulmonary sites of small cell cancer, is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H901731249\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGIC ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell neuroendocrine carcinoma of the cervix is a rare disease, accounting for only up to 2 percent of all invasive cervical cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/3-7,9\">",
"     3-7,9",
"    </a>",
"    ]. In a series from the Surveillance, Epidemiology and End Results (SEER) database, the mean annual incidence in the US from 1977 to 2003 was 0.06 per 100,000 women, compared with 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/10\">",
"     10",
"    </a>",
"    ]. Five-year survival for small cell neuroendocrine carcinoma was worse than for squamous cell or adenocarcinoma (36 versus 61 and 70 percent, respectively).",
"   </p>",
"   <p>",
"    Although the disease has been described in women from 22 to 87 years of age, the mean age at diagnosis of small cell neuroendocrine carcinoma of the cervix is about 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. The large cell variant accounts for a minority of cases. The mean age at diagnosis of the large cell variant is 34 years, but the range is wide (from 21 to 62) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/19\">",
"     19",
"    </a>",
"    ]. An association with high-risk HPV infection (HPV18 more than HPV 16) has been described for both small cell and its large cell neuroendocrine cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/18,20-23\">",
"     18,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small cell lung cancers are strongly associated with smoking. Although smoking is a poor prognostic factor for cervical small cell neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/24\">",
"     24",
"    </a>",
"    ], an etiologic link has not been established.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\", section on 'Smoking'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Epidemiology'",
"    </a>",
"    .)",
"    <strong>",
"     &nbsp;",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1336437721\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, under both light and electron microscopy, the characteristics of pure small cell neuroendocrine carcinoma of the cervix are indistinguishable from small cell carcinoma of the lung and extrapulmonary small cell carcinoma of other sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microscopic findings on hematoxylin-eosin (H&amp;E) stained sections include a poorly differentiated, diffusely infiltrating tumor composed of small blue cells with scant cytoplasm, and hyperchromatic nuclei with finely dispersed chromatin, and absent or inconspicuous nucleoli. The cells of the large cell variant of small cell neuroendocrine carcinoma are distinguished by the presence of prominent nucleoli, vesicular nuclei with a more granular chromatin pattern, and variable amounts of cytoplasm. Neuroendocrine differentiation is demonstrated with pan-neuroendocrine markers such as chromogranin A, synaptophysin and neuron-specific enolase. (See",
"    <a class=\"local\" href=\"#H901732262\">",
"     'Immunohistochemistry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both large and small cell types may be present in the same tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. In either case, the neoplastic cells are typically arranged in clusters, sheets, or trabeculae, separated by a delicate fibrovascular stroma. Nuclear molding is a distinctive and characteristic finding in well-preserved specimens, although a nondiagnostic \"crush\" artifact is more frequently observed. Mitotic rates are high, and necrosis of individual tumor cells is common. The natural history and treatment of large cell NEC is similar to small cell neuroendocrine carcinoma and will not be discussed separately.",
"   </p>",
"   <p>",
"    In some cases, there are admixed foci of in situ or invasive adenocarcinoma or squamous cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/18,24-26\">",
"     18,24-26",
"    </a>",
"    ]. In such cases, the small cell neuroendocrine component, even if small, dictates the prognosis as well as the treatment plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27033407\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other small round blue cell tumors that can arise in the cervix and may mimic small cell neuroendocrine carcinoma include basaloid squamous cell carcinoma, embryonal rhabdomyosarcoma, lymphoma, and undifferentiated carcinoma arising from the lower uterine segment. These are usually excluded by immunohistochemical analysis. In addition, small cell neuroendocrine carcinoma must be differentiated from poorly differentiated squamous cell cancer with neuroendocrine features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=see_link&amp;anchor=H5#H5\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Genitourinary tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H901732262\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their epithelial cellular origin, virtually all small cell neuroendocrine carcinomas are immunoreactive for keratin and epithelial membrane antigen. The differential diagnosis includes cervical adenocarcinomas, adenosquamous cancer, or poorly differentiated squamous cell cancer. &nbsp;",
"   </p>",
"   <p>",
"    Neuroendocrine and neural differentiation results in the expression of neuron-specific enolase (NSE), synaptophysin, chromogranin A (CGA), and CD56 (neural cell adhesion molecule [NCAM]). Immunohistochemical staining for these markers of neuroendocrine differentiation can be used to support the diagnosis of a small cell neuroendocrine carcinoma. At least one marker is expressed in 88 to 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16,27\">",
"     16,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The percentage of cases reactive with each varies in different studies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For small cell neuroendocrine carcinomas:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CGA reactivity is reported in 50 to 76 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16,27,28\">",
"       16,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Synaptophysin reactivity is reported in 60 to 90 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16,27,28\">",
"       16,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NSE expression is reported in up to 75 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD56 expression, thought to be the most sensitive marker for the diagnosis of small cell neuroendocrine carcinoma, was reported in 71 and 92 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16,28\">",
"       16,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large cell neuroendocrine carcinomas also express neuroendocrine markers, although only approximately 25 to 38 percent express CGA, and synaptophysin expression is quite variable [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/19,28-30\">",
"       19,28-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1336437728\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell neuroendocrine carcinoma of the cervix typically arise in the cervical or endocervical epithelium. The diagnosis is usually made on a gynecologic exam performed because of symptoms such as vaginal bleeding or discharge, pelvic pain, pressure, or weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]. A few patients are asymptomatic and diagnosed on the basis of an abnormal PAP smear.",
"   </p>",
"   <p>",
"    A cervical mass can often be identified on examination, and the majority have bulky disease at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]. In a review of 188 patients with small cell neuroendocrine carcinoma of the cervix, 135 had stage I-IIA disease, 45 had IIB-IVA, and eight had stage IVB disease; of the patients whose tumor size was recorded, 80 percent were &ge;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1336437735\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Often, the presentation is that of a pelvic mass with bulky pelvic adenopathy or malignant ascites. Similar to small cell lung cancer, small cell neuroendocrine carcinoma have a particular propensity to spread to the liver, adrenals, bone, bone marrow, and the brain. Also in parallel to small cell lung cancer, small cell neuroendocrine carcinoma of the cervix can occasionally present with a paraneoplastic syndrome such as the syndrome of inappropriate antidiuretic hormone secretion [SIADH], Cushing&rsquo;s syndrome, hypercalcemia, or a neurologic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy is required for a histologic diagnosis. However, cytology, endocervical curettage, or cervical biopsy might not adequately differentiate small cell neuroendocrine carcinoma from a squamous cell cancer or adenocarcinoma of the cervix; immunohistochemical staining for markers of neural and neuroendocrine differentiation may be helpful, but sometimes larger samples including hysterectomy are required to establish the diagnosis. (See",
"    <a class=\"local\" href=\"#H901732262\">",
"     'Immunohistochemistry'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1336437735\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H987722005\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell neuroendocrine carcinomas are often not confined to the cervix and surrounding tissues at diagnosis. Bone, supraclavicular lymph nodes, liver, and lung are the most common sites of extrapelvic disease spread.",
"   </p>",
"   <p>",
"    The initial evaluation should include a gynecologic examination and computed tomography (CT) of the abdomen and pelvis for assessment of the extent of locoregional disease as well as distant spread and a CT of the chest to rule out a primary small cell lung cancer.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is being increasingly used for staging of any cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]. A clinical document from the Society of Gynecologic Oncologists on neuroendocrine tumors of the gynecologic tract states that given the high rate of distant metastatic spread that a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging may be reasonable to consider for small cell neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the benefit of routine",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    staging compared to a high-quality CT scan performed with a multi-detector row CT scanner has not been assessed.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is more expensive and time consuming, and requires injection of a radioactive isotope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Staging workup'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Workup may include a bone marrow aspiration and biopsy, if the finding of bone marrow metastases would change management. Otherwise, we do not routinely perform bone marrow aspiration and biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Staging workup'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain metastases are frequent in pulmonary small cell tumors; CNS imaging is usually recommended as a component of the initial staging evaluation. However, head CT is not usually required for small cell neuroendocrine carcinoma. One series found no cranial metastases at initial presentation in a 14-year retrospective experience [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/32\">",
"     32",
"    </a>",
"    ]. Brain imaging is generally only warranted in the presence of lung metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H987722012\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of small cell neuroendocrine carcinoma of the cervix depends upon disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Because of the histologic, prognostic, and therapeutic similarities between cervical small cell neuroendocrine carcinoma and small cell lung cancer, the staging of small cell neuroendocrine carcinoma has often been adapted to the two-stage staging system widely used for small cell lung cancer, as originally defined by the Veterans&rsquo; Affairs Lung Study Group (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Staging'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited-stage disease, which can be encompassed within a single radiotherapy port, is generally treated with combined modality therapy; five-year survival rates are approximately 30 percent.",
"     </li>",
"     <li>",
"      Extensive-stage disease (defined as disease outside of these confines) is associated with a dismal prognosis, with few survivors beyond two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This two-tiered staging system recognizes the systemic nature of the disease and also serves to define a subset of patients who might benefit from combined modality therapy. (See",
"    <a class=\"local\" href=\"#H1336437742\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However,",
"    <span class=\"nowrap\">",
"     FIGO/AJCC",
"    </span>",
"    TNM staging system for cervical cancer includes small cell neuroendocrine carcinoma and other neuroendocrine variants, and is increasingly being used for staging of the disease (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 2",
"    </a>",
"    ). While the TNM staging system describes the extent and burden of disease more accurately than does the simple designation of limited versus extensive stage disease, there is overlap in prognosis and therapy between stage groupings, particularly stages II and III. In most series, patients with stage I-IIA disease fare better than do those with more advanced stage disease (five-year survival 37 versus 9 percent in one review of 188 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]), but the value of additional stratification, particularly beyond stage I disease, is unclear.",
"   </p>",
"   <p>",
"    In one series of 239 cases of small cell neuroendocrine carcinoma, the stage distribution at diagnosis was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &ndash; 42 percent",
"     </li>",
"     <li>",
"      Stage II &ndash; 19 percent",
"     </li>",
"     <li>",
"      Stge III &ndash; 10 percent",
"     </li>",
"     <li>",
"      Stage IV &ndash; 23 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1336437742\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of the condition, there are limited data to guide treatment of small cell neuroendocrine carcinoma. Most published series contain few patients, and there are no prospective trials. In general, survival is poor with radical hysterectomy alone, but there is no consensus as to optimal management [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. Treatment considerations generally take into account the treatment options for cervical cancer and particularly for chemotherapy, have been largely extrapolated from the experience with small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13,14,16,17,23,32-36\">",
"     13,14,16,17,23,32-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most clinicians favor the use of combined modality therapy (surgery followed by chemotherapy or combined chemoradiotherapy) for limited-stage potentially resectable disease, definitive chemoradiotherapy for locoregionally advanced unresectable but nonmetastatic disease, and palliative chemotherapy alone for those with metastatic disease, using chemotherapy regimens that are typically used for small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H987722153\">",
"    <span class=\"h2\">",
"     Issues in early stage disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970644721\">",
"    <span class=\"h3\">",
"     Benefit of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with early stage disease will not have metastases at presentation and are potentially curable with local therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/6,37\">",
"     6,37",
"    </a>",
"    ]. However, given the propensity for early dissemination and patterns of treatment failure (with distant metastases predominating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]), and the sensitivity of small cell neuroendocrine cancers to platinum-based chemotherapy, systemic chemotherapy is considered a critical component of standard therapy for all stages of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of systemic chemotherapy as a component of multimodality for small cell neuroendocrine carcinoma can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 17 patients with small cell neuroendocrine carcinoma, treatment consisted of primary surgery with or without individualized adjuvant treatment (radiation therapy [RT], concurrent chemoradiation therapy, or chemotherapy alone), definitive RT or chemoradiotherapy, or chemotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/38\">",
"       38",
"      </a>",
"      ]. Adjuvant RT was administered as whole pelvic external-beam RT with or without additional brachytherapy, with a total median dose of 50 Gy over five weeks. Primary definitive RT was administered as external-beam pelvic RT followed by additional brachytherapy, with a total median dose of 79.5 Gy. Concurrent chemotherapy was administered in the form of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on day 1 and IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      daily for three days, every three weeks for four cycles. The first two cycles of etoposide were given concurrently with RT (on days 1 and 22). The subsequent two cycles were given after RT. During RT, the etoposide was given on days 1, 3, and 5 of each cycle to improve tolerance. Following RT, the etoposide was given on days 1, 2, and 3 of each cycle. Chemotherapy alone was administered in the form of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (dosed at an area under the curve [AUC] of concentration x time of 4 to 5) and etoposide (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every three to four weeks. Issues related to dosing of carboplatin are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Extent of disease was the only significant prognostic factor for survival. Median overall survival was significantly better for patients with early stage (IA1-IB2) compared to those with advanced stage disease (stage IIB-IV, 31 versus 6 months, p=0.034). However, in the early stage disease group, the three-year distant recurrence-free survival rate was significantly better for those patients who received chemotherapy as a component of treatment compared to those who did not (83 versus 0 percent, p=0.025). All five patients with early stage disease who did not receive chemotherapy as part of their initial treatment developed distant metastases within two years of diagnosis. In contrast only one of six patients who were treated with adjuvant platinum and etoposide-based combination therapy developed systemic disease.",
"     </li>",
"     <li>",
"      Benefit for chemotherapy was also shown in a series of 23 women with small cell neuroendocrine carcinoma, in whom adjuvant chemotherapy with either PVB (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ) or",
"      <span class=\"nowrap\">",
"       VAC/PE",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , alternating with cisplatin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) was administered after radical hysterectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/36\">",
"       36",
"      </a>",
"      ]. At a median follow-up of 41 months, 10 of 14 patients receiving",
"      <span class=\"nowrap\">",
"       VAC/PE",
"      </span>",
"      were alive as compared to only three of nine receiving PVB. These data support the viewpoint that chemotherapy regimens containing a combination of vincristine, doxorubicin and cyclophosphamide or cisplatin and etoposide (typical of those used for treatment of small cell lung cancer) are effective in patients with early stage small cell neuroendocrine carcinoma after radical hysterectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1143487\">",
"    <span class=\"h3\">",
"     Chemotherapy alone versus chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing chemotherapy alone versus chemoradiotherapy, either as primary therapy, or in the adjuvant setting following radical hysterectomy. The available retrospective series addressing the benefits of chemoradiotherapy versus chemotherapy alone are of limited utility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lack of benefit for adjuvant chemoradiotherapy rather than chemotherapy alone was suggested in a report of 68 patients with stage IB-IIA small cell neuroendocrine carcinoma of the cervix [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment consisted of radical surgery alone in seven, neoadjuvant chemotherapy followed by radical surgery with or without RT in 11, radical surgery followed by adjuvant chemotherapy in 24, and radical surgery followed by RT or chemoradiotherapy in 26. Several different chemotherapy regimens were used.",
"      <br/>",
"      <br/>",
"      The estimated two- and five-year survival rates were 65 and 47 percent, respectively. In multivariate analysis, FIGO stage was the only independent predictor of outcome; patients with stage IB1 disease had significantly better five-year survival than did those with IB2 or IIA disease (55 versus 32 percent). There was a trend toward better survival with adjuvant chemotherapy, but it was not statistically significant (five-year survival 49 versus 42 percent with and without adjuvant chemotherapy). In addition, adjuvant chemoradiotherapy did not improve survival compared to adjuvant chemotherapy alone.",
"     </li>",
"     <li>",
"      On the other hand, support for the benefit of RT is provided by another series of 34 patients with small cell neuroendocrine carcinoma, which included 21 patients with FIGO stage I disease, six with stage II disease, and seven with stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/14\">",
"       14",
"      </a>",
"      ]. Overall, 23 had a hysterectomy as a component of therapy; of these, 14 received adjuvant therapy with RT (n = 11), chemoradiotherapy (n = 3)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy (n = 1). Ten women had primary RT without or with (n = 5) chemotherapy. In multivariate analysis, smoking and advanced stage disease were the only independent prognostic factors for survival. However, four of the six women in this series who were cured of their disease had received hysterectomy followed by postoperative RT with or without chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the lack of data, most clinicians favor the use of combined chemotherapy and RT because of the strong evidence supporting concurrent chemoradiotherapy in other subtypes of cervical cancer. Adjuvant chemotherapy alone could be considered an option in patients who have undergone radical hysterectomy.",
"   </p>",
"   <p>",
"    We pattern the chemotherapy and RT on that utilized for small cell lung cancer. Whole pelvis external beam RT with or without brachytherapy is administered using techniques as outlined for other histologic varieties of cervical cancer. We administer concurrent chemotherapy in the form of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on day 1 and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    daily for three days, every three weeks for four cycles. The specifics of the",
"    <span class=\"nowrap\">",
"     cisplatin/etoposide",
"    </span>",
"    chemotherapy regimen are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first two cycles can be given concurrently with RT (on days 1 and 22). The subsequent two cycles are given after RT. Substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is appropriate for patients with preexisting renal dysfunction or peripheral neuropathy (",
"    <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"     table 4",
"    </a>",
"    ). Issues related to dosing of carboplatin are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\", section on 'Integration with chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H10#H10\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Carboplatin plus etoposide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915770#H618915770\">",
"     \"Management of early stage cervical cancer\", section on 'Primary radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H970645456\">",
"    <span class=\"h3\">",
"     Contribution of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality treatment with chemotherapy and RT are the cornerstone of current management of small cell lung cancer, and surgery generally plays a minor role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=see_link\">",
"     \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of surgery for small cell neuroendocrine carcinoma is not well studied; however, a role for surgery in patients with apparently early stage disease is supported by the fact that most series report long-term survival only for those patients who have undergone surgical resection in the context of multimodality treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The contribution of surgery to outcomes was shown in a combined analysis of 188 patients derived from both institutional experience and literature review, radical hysterectomy was an independent prognostic factor for survival in multivariate analysis (as was early stage disease and the use of any chemotherapy). Among patients with stage I-IIA disease, five-year survival was significantly higher for those undergoing versus not undergoing radical hysterectomy (38 versus 24 percent, p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"     13",
"    </a>",
"    ]. However, because of the retrospective nature of the study, the contribution of the surgical procedure may have been overestimated because patients who were fit to undergo and selected for radical hysterectomy may have a better prognosis than those patients who were not selected to undergo surgery.",
"   </p>",
"   <p>",
"    On the other hand, the curative potential of definitive chemoradiotherapy was shown in a single institution series of 31 patients who were treated on protocols using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , followed by concurrent chemoradiotherapy, with or without the addition of post-chemoradiation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and paclitaxel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/32\">",
"     32",
"    </a>",
"    ]. Twenty-nine patients had a cervical biopsy alone whereas five had hysterectomy; prophylactic cranial irradiation was optional. The three-year failure-free rate of the patients with early stage disease (stage I or II) was 80 percent, and it was 38 percent for those with stage III or IV disease. Local failure occurred in approximately 13 percent. The authors concluded that approximately 55 percent of patients could be successfully treated with a combination of RT and cisplatin-based chemotherapy.",
"   </p>",
"   <p>",
"    There are no prospective trials to compare surgery versus primary chemoradiotherapy for small, potentially resectable small cell neuroendocrine carcinoma, and it is unclear which patients, if any, should undergo radical hysterectomy as opposed to primary combined chemotherapy and RT. A clinical document on small cell neuroendocrine carcinoma issued by the Society of Gynecologic Oncologists in 2011 recommended the following approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early stage (I-IIA disease)",
"      <strong>",
"       &le;4 cm",
"      </strong>",
"      &ndash; Radical hysterectomy with lymphadenectomy followed by chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without RT",
"     </li>",
"     <li>",
"      Early stage (I-IIA disease)",
"      <strong>",
"       &gt;4 cm",
"      </strong>",
"      &ndash; EITHER combined chemotherapy and RT OR neoadjuvant platinum-based chemotherapy followed by surgery if the disease remains localized",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our view, initial surgery is an appropriate option for patients with small (&lt;4 cm) cervical lesions with no clear parametrial disease and no evidence of metastatic disease. For a tumor &gt;4 cm with known small cell histology, we begin with combined modality therapy (chemotherapy and RT). Surgery can then be considered in the adjuvant setting if the patient responds to the primary treatment and there continues to be no evidence of metastatic disease.",
"   </p>",
"   <p>",
"    Often, the diagnosis of small cell is not made until receipt of the final pathology on a radical hysterectomy; once the diagnosis is established, combined modality therapy should be initiated promptly. RT can be administered as whole pelvic external beam RT with or without additional brachytherapy. We administer concurrent chemotherapy in the form of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on day 1 and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    daily for three days, every three weeks for four cycles. The first two cycles can be given concurrently with RT (on days 1 and 22). The subsequent two cycles are given after RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22275865\">",
"    <span class=\"h3\">",
"     Role of node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of lymph node dissection in patients with small cell neuroendocrine carcinoma is not defined. In clinically early stage disease, information about locoregional nodal status might help guide RT planning if a radical hysterectomy is being planned as part of initial treatment. However, the value of surgical staging is not clear and routine lymph node dissection is often not undertaken if the initial treatment plan is for chemoradiation. A Clinical Document on treatment of small cell neuroendocrine carcinoma issued by the SGO in 2011 recommended lymphadenectomy in patients undergoing radical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135251\">",
"    <span class=\"h4\">",
"     Fertility sparing surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about fertility preservation are particularly common among women with gynecologic malignancies. For women who have low-risk squamous cell cervical cancer, fertility preserving surgery may be an appropriate alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=see_link\">",
"     \"Fertility sparing surgery for invasive cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management dilemma in young women with small cell neuroendocrine carcinoma who desire to preserve fertility is complicated by the inherent biology of this tumor type. Small cell neuroendocrine carcinoma is distinguished from squamous cell carcinoma of the cervix by its rapid growth characteristics and the early development of widespread metastases. While small cell neuroendocrine carcinoma is extremely sensitive to both chemotherapy and RT, the majority of patients relapse within two years. Even with an early stage presentation, the prognosis is distinctly worse as compared to the more common non-small cell cervical carcinomas. Due to the early propensity for hematogenous spread despite locally negative resection margins and due to the limited prognosis, fertility-sparing surgery is not a recommended treatment option for young patients with small cell neuroendocrine carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H987721709\">",
"    <span class=\"h3\">",
"     Role of prophylactic cranial irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with limited stage small cell lung cancer who achieve a complete response to initial treatment, prophylactic cranial irradiation (PCI) can decrease the incidence of brain metastases and prolong survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link&amp;anchor=H4#H4\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\", section on 'Limited stage SCLC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials that address the benefit of PCI in women with small cell neuroendocrine carcinoma of the cervix. Some information is available from a series that reported the outcome and patterns of failure on 21 patients with small cell neuroendocrine carcinoma treated locally with either radical hysterectomy (n = 6) or RT (n = 15), and systemically (13 of 21) with combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16\">",
"     16",
"    </a>",
"    ]. No patient received PCI.",
"   </p>",
"   <p>",
"    Overall survival was 29 percent at five years, and the mean time to first relapse was 8.4 months (range, 3.6 to 28 months). None of the women with disease beyond stage IB1 survived longer than 30 months. Twelve of the 14 relapses were distant hematogenous metastases, and no patients failed in the brain as the sole site of first recurrence. Two patients developed simultaneous brain and lung metastases, suggesting that lung involvement may be a necessary precursor to brain failure and that PCI may not play as crucial a role in the management of small cell carcinoma of the cervix as it plays in small cell carcinoma of the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22276264\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective trials to compare surgery versus primary chemoradiotherapy for small, potentially resectable small cell neuroendocrine carcinomas, and it is unclear which patients, if any, should undergo radical hysterectomy as opposed to primary combined chemotherapy and RT. In keeping with guidelines from the SGO, we prefer initial surgery (radical hysterectomy and lymphadenectomy) for patients with small (&lt;4 cm) cervical lesions and no evidence of metastatic disease. Following surgery, we administer combined modality adjuvant therapy with chemotherapy and concurrent RT because of the strong evidence supporting concurrent chemoradiotherapy in other subtypes of cervical cancer and the high incidence of distant metastases in patients with small cell neuroendocrine carcinoma.",
"   </p>",
"   <p>",
"    We pattern the chemotherapy and RT on that utilized for small cell lung cancer. Whole pelvis external beam RT with or without brachytherapy is administered using techniques as outlined for other histologic varieties of cervical cancer. We administer concurrent chemotherapy in the form of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on day 1 and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    daily for three days, every three weeks for four cycles. The specifics of the",
"    <span class=\"nowrap\">",
"     cisplatin/etoposide",
"    </span>",
"    chemotherapy regimen are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 3",
"    </a>",
"    ). The first two cycles can be given concurrently with RT (on days 1 and 22). The subsequent two cycles are given after RT.",
"   </p>",
"   <p>",
"    For a tumor &gt;4 cm with known small cell histology, we begin with combined modality therapy (chemotherapy and RT as described above). Surgery can then be considered in the adjuvant setting if the patient responds to the primary treatment and there continues to be no evidence of metastatic disease.",
"   </p>",
"   <p>",
"    The role of PCI remains uncertain, and we do not advocate its use for most patients with early stage disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22276031\">",
"    <span class=\"h2\">",
"     Advanced stage and recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy with RT is used for locally advanced unresectable but nonmetastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]. As with earlier stage disease, we pattern the chemotherapy and RT on that utilized for small cell lung cancer. Whole pelvis external beam RT with or without brachytherapy is administered using techniques as outlined for other histologic varieties of cervical cancer. We administer concurrent chemotherapy in the form of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on day 1 and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    daily for three days, every three weeks for four cycles. The specifics of the",
"    <span class=\"nowrap\">",
"     cisplatin/etoposide",
"    </span>",
"    chemotherapy regimen are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first two cycles can be given concurrently with RT (on days 1 and 22). The subsequent two cycles are given after RT. Substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is appropriate for patients with preexisting renal dysfunction or peripheral neuropathy (",
"    <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"     table 4",
"    </a>",
"    ). Issues related to dosing of carboplatin are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\", section on 'Integration with chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H10#H10\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Carboplatin plus etoposide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915770#H618915770\">",
"     \"Management of early stage cervical cancer\", section on 'Primary radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with widespread metastatic or recurrent disease are treated with chemotherapy regimens similar to those used for treatment of small cell lung cancer, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22275531\">",
"    <span class=\"h2\">",
"     Prognosis and prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major adverse prognostic factors are advanced tumor stage, larger tumor size, pure small cell histology, and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/14,36,39,40\">",
"     14,36,39,40",
"    </a>",
"    ]. In one study, the only survivors were those with tumors &lt;4 cm and no clinical evidence of nodal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis is somewhat better than for small cell lung cancer. The reported five-year survival is 29 to 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/11,16\">",
"     11,16",
"    </a>",
"    ], while for patients with early stage disease who are treated with multimodality therapy, some series report up to 80 percent three-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/32,38\">",
"     32,38",
"    </a>",
"    ]. In contrast, only about 10 to 13 percent of patients with limited stage small cell lung cancer and 1 to 2 percent of those with extensive stage disease are alive at five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188859445\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness has not been well studied. For squamous cell cancers and adenocarcinomas, the main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy (which is most likely with a central pelvic recurrence). In general, restaging studies to discover asymptomatic metastatic disease that is not curable are not endorsed by any guideline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=see_link\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to cervical squamous cell and adenocarcinoma, the predominant site of failure for small cell neuroendocrine carcinoma is distant rather than pelvic. The Clinical Document from the SGO on treatment of small cell neuroendocrine carcinoma suggested that posttreatment assessment include symptom review and pelvic examination as well as periodic full body imaging, but they did not make a specific recommendation as to the frequency or nature of the posttreatment surveillance strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, a guideline on posttreatment surveillance in women with cervical cancer from the SGO indicated that there were insufficient data to support routine use of routine radiographic imaging, including CT, but did not make a specific recommendation for small cell neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/23/5498/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=see_link\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=see_link&amp;anchor=H19976081#H19976081\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\", section on 'Society of Gynecologic Oncology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical practice is variable. Although therapy of recurrent disease is palliative and not curative, survival and quality of life may be benefited by salvage chemotherapy, as with small cell lung cancer. In our view, it is reasonable to consider CT or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan imaging every three to six months or at any time there is suspicion for recurrence based on symptoms or physical exam findings, if the patient would be considered a candidate for additional therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\", section on 'Chemotherapy versus best supportive care'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H901730062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small cell neuroendocrine carcinoma of the uterine cervix is a rare, aggressive subtype of cervical cancer that is characterized by a high frequency of lymph node metastases and early hematogenous dissemination. A less common large cell variant shares the same natural history and is categorized and treated similarly.",
"      <br/>",
"      <br/>",
"      The natural history of small cell neuroendocrine carcinoma is significantly worse than that of the more commonly seen squamous cell cancer or adenocarcinomas. These tumors are considered to represent an extrapulmonary variant of small cell lung cancer. (See",
"      <a class=\"local\" href=\"#H1336437714\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link&amp;anchor=H2#H2\">",
"       \"Extrapulmonary small cell cancer\", section on 'Overview of ESCC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients with early stage disease will not have metastases at presentation and are potentially curable with local therapies, but because of the frequency of systemic disease at presentation and the predominant pattern of distant failure after primary treatment, systemic chemotherapy is a component of standard therapy for all stages of disease. (See",
"      <a class=\"local\" href=\"#H970644721\">",
"       'Benefit of chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to treatment, patients should be evaluated to determine whether or not distant metastases are present, and to rule out a primary small cell lung cancer. Brain imaging is only warranted in the presence of lung metastases. (See",
"      <a class=\"local\" href=\"#H1336437735\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22276363\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to guide treatment of small cell neuroendocrine carcinoma, and treatment principles have been patterned both on management guidelines for cervical cancer and extrapolated from the experience with small cell lung cancer. The following represents our approach to treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with early stage disease (FIGO stage I-IIA, (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      )), tumor size &le; 4 cm, and no metastatic disease, we suggest initial surgery rather than platinum-based combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H970645456\">",
"       'Contribution of surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Following surgery, we recommend prompt initiation of postoperative adjuvant therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Chemotherapy in conjunction with RT is frequently used, but chemotherapy alone is an option. (See",
"      <a class=\"local\" href=\"#H1143487\">",
"       'Chemotherapy alone versus chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We generally prefer combined modality therapy, patterning treatment on that utilized for small cell lung cancer. Whole pelvis external beam RT with or without brachytherapy is administered using techniques as outlined for other histologic varieties of cervical cancer. We administer concurrent chemotherapy in the form of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on day 1 and IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      daily for three days, every three weeks for four cycles. The specifics of the",
"      <span class=\"nowrap\">",
"       cisplatin/etoposide",
"      </span>",
"      chemotherapy regimen are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef66855 \" href=\"UTD.htm?42/23/43389\">",
"       table 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The first two cycles can be given concurrently with RT (on days 1 and 22). The subsequent two cycles are given after RT. Substitution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      for cisplatin is appropriate for patients with preexisting renal dysfunction or peripheral neuropathy (",
"      <a class=\"graphic graphic_table graphicRef75586 \" href=\"UTD.htm?40/39/41597\">",
"       table 4",
"      </a>",
"      ). Issues related to dosing of carboplatin are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link&amp;anchor=H9#H9\">",
"       \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\", section on 'Integration with chemotherapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H10#H10\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Carboplatin plus etoposide'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915770#H618915770\">",
"       \"Management of early stage cervical cancer\", section on 'Primary radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with early stage disease (FIGO stage I-IIA, (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      )), tumor size &gt;4 cm, and no evidence of metastatic disease, or for non-surgical candidates, we suggest initial combined chemotherapy and RT instead if surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery could then be considered in the adjuvant setting if the patient responds to the primary treatment and there continues to be no evidence of metastatic disease.",
"     </li>",
"     <li>",
"      In contrast to small cell lung cancer, the role of prophylactic cranial irradiation (PCI) in this situation is not established for small cell neuroendocrine carcinoma of the cervix, and in general, we suggest not pursuing PCI outside of the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H987721709\">",
"       'Role of prophylactic cranial irradiation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with stage IIB-IVA disease (",
"      <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"       table 2",
"      </a>",
"      ), we suggest integrated chemoradiotherapy as outlined above.",
"     </li>",
"     <li>",
"      For patients who present with metastatic disease, we suggest chemotherapy alone using a regimen as used for small cell lung cancer (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Posttreatment surveillance should include symptom review and pelvic examination; periodic full body imaging is optional. (See",
"      <a class=\"local\" href=\"#H188859445\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER data for 2003-2007:  file://seer.cancer.gov/ (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/2\">",
"      Alfsen GC, Thoresen SO, Kristensen GB, et al. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000; 89:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/3\">",
"      Albores-Saavedra J, Larraza O, Poucell S, Rodr&iacute;guez Mart&iacute;nez HA. Carcinoid of the uterine cervix: additional observations on a new tumor entity. Cancer 1976; 38:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/4\">",
"      Scully RE, Aguirre P, DeLellis RA. Argyrophilia, serotonin, and peptide hormones in the female genital tract and its tumors. Int J Gynecol Pathol 1984; 3:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/5\">",
"      Miller B, Dockter M, el Torky M, Photopulos G. Small cell carcinoma of the cervix: a clinical and flow-cytometric study. Gynecol Oncol 1991; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/6\">",
"      Van Nagell JR Jr, Donaldson ES, Wood EG, et al. Small cell cancer of the uterine cervix. Cancer 1977; 40:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/7\">",
"      Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997; 121:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/8\">",
"      REAGAN JW, HAMONIC MJ, WENTZ WB. Analytical study of the cells in cervical squamous-cell cancer. Lab Invest 1957; 6:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/9\">",
"      McCusker ME, Cot&eacute; TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003; 88:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/10\">",
"      Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol 2008; 111:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/11\">",
"      Sevin BU, Lu Y, Bloch DA, et al. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer 1996; 78:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/12\">",
"      Sheets EE, Berman ML, Hrountas CK, et al. Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol 1988; 71:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/13\">",
"      Cohen JG, Kapp DS, Shin JY, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol 2010; 203:347.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/14\">",
"      Chan JK, Loizzi V, Burger RA, et al. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 2003; 97:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/15\">",
"      Sevin BU, Method MW, Nadji M, et al. Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 1996; 77:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/16\">",
"      Viswanathan AN, Deavers MT, Jhingran A, et al. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004; 93:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/17\">",
"      Boruta DM 2nd, Schorge JO, Duska LA, et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol 2001; 81:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/18\">",
"      Abeler VM, Holm R, Nesland JM, Kj&oslash;rstad KE. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer 1994; 73:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/19\">",
"      Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol 1997; 21:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/20\">",
"      Mannion C, Park WS, Man YG, et al. Endocrine tumors of the cervix: morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. Cancer 1998; 83:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/21\">",
"      Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 1991; 4:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/22\">",
"      Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/23\">",
"      Wang KL, Yang YC, Wang TY, et al. Neuroendocrine carcinoma of the uterine cervix: A clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother 2006; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/24\">",
"      Lee JM, Lee KB, Nam JH, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol 2008; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/25\">",
"      Conner MG, Richter H, Moran CA, et al. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol 2002; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/26\">",
"      Ishida GM, Kato N, Hayasaka T, et al. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol 2004; 23:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/27\">",
"      Straughn JM Jr, Richter HE, Conner MG, et al. Predictors of outcome in small cell carcinoma of the cervix--a case series. Gynecol Oncol 2001; 83:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/28\">",
"      McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol 2010; 34:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/29\">",
"      Krivak TC, McBroom JW, Sundborg MJ, et al. Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature. Gynecol Oncol 2001; 82:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/30\">",
"      Sato Y, Shimamoto T, Amada S, et al. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol 2003; 22:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/31\">",
"      Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 2011; 122:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/32\">",
"      Hoskins PJ, Swenerton KD, Pike JA, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 2003; 21:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/33\">",
"      Collinet P, Lanvin D, Declerck D, et al. Neuroendocrine tumors of the uterine cervix. Clinicopathologic study of five patients. Eur J Obstet Gynecol Reprod Biol 2000; 91:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/34\">",
"      Chang TC, Hsueh S, Lai CH, et al. Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer. Anticancer Drugs 1999; 10:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/35\">",
"      Sykes AJ, Shanks JH, Davidson SE. Small cell carcinoma of the uterine cervix: a clinicopathological review. Int J Oncol 1999; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/36\">",
"      Chang TC, Lai CH, Tseng CJ, et al. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998; 83:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/37\">",
"      Randall ME, Kim JA, Mills SE, et al. Uncommon variants of cervical carcinoma treated with radical irradiation. A clinicopathologic study of 66 cases. Cancer 1986; 57:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/38\">",
"      Zivanovic O, Leitao MM Jr, Park KJ, et al. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol 2009; 112:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/39\">",
"      Hirahatake K, Hareyama H, Kure R, et al. Cytologic and hormonal findings in a carcinoid tumor of the uterine cervix. Acta Cytol 1990; 34:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/40\">",
"      Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003; 21:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/23/5498/abstract/41\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13930 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5498=[""].join("\n");
var outline_f5_23_5498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H901730062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1336437714\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H901731249\">",
"      EPIDEMIOLOGY AND ETIOLOGIC ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1336437721\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27033407\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H901732262\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1336437728\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1336437735\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H987722005\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H987722012\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1336437742\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H987722153\">",
"      Issues in early stage disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H970644721\">",
"      - Benefit of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1143487\">",
"      - Chemotherapy alone versus chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H970645456\">",
"      - Contribution of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22275865\">",
"      - Role of node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1135251\">",
"      Fertility sparing surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H987721709\">",
"      - Role of prophylactic cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22276264\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22276031\">",
"      Advanced stage and recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22275531\">",
"      Prognosis and prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188859445\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H901730062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22276363\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/13930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/13930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/38/2668\" title=\"table 1\">",
"      Histopathology cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 2\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43389\" title=\"table 3\">",
"      Cisplatin 80 plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/39/41597\" title=\"table 4\">",
"      Carboplatin plus etoposide for small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9898?source=related_link\">",
"      Fertility sparing surgery for invasive cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/42/17064?source=related_link\">",
"      Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_23_5499="False positive visible blood";
var content_f5_23_5499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common foods and drugs that can cause the stool to appear bloody",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Antibiotics (ampicillin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bismuth preparations (Pepto-Bismol, Maalox, Kaopectate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red-dyed snack foods (eg, spicy \"red-hot\" snacks)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chocolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavored gelatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kool-Aid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red licorice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large quantities of some dark green foods",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5499=[""].join("\n");
var outline_f5_23_5499=null;
var title_f5_23_5500="Risk of BRCA1 mutation";
var content_f5_23_5500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relationship between family history of breast and ovarian cancer and likelihood of BRCA1 mutation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chance of BRCA1 mutation, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Single affected patient",
"       </td>",
"       <td>",
"        In individual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer, &lt;age 30",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer, ages 30-39",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer, ages 40-49",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ovarian cancer, &lt;age 50",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sisters",
"       </td>",
"       <td>",
"        In family",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 breast cancers, &lt;age 40",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2  breast cancers, ages 40-49",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer &lt;age 50, ovarian cancer&nbsp;&lt;age 50",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 ovarian cancers, &lt;age 50",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;3 breast cancers, all before age 50",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2 breast cancers, &ge;1 ovarian cancer",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2 breast cancers, &ge;2 ovarian cancers",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Greene, MH, Mayo Clin Proc 1997; 72:54.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5500=[""].join("\n");
var outline_f5_23_5500=null;
var title_f5_23_5501="Causes of refractory or recurrent peptic ulcer disease";
var content_f5_23_5501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of refractory or recurrent peptic ulcer disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persisting",
"        <em>",
"         H. pylori",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor compliance with treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resistant organism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate",
"        <em>",
"         H. pylori",
"        </em>",
"        regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Unrecognized",
"        <em>",
"         H. pylori",
"        </em>",
"        infection:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        False negative",
"        <em>",
"         H. pylori",
"        </em>",
"        testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Skipped or inadequate testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ulcers related to nonsteroidal antiinflammatory drugs (NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continued NSAID use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undiscovered NSAID use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor response to PPI co-therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other mechanisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Impaired healing:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dense fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cigarette smoking, especially heavy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Giant ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inadequate inhibition of acid secretion:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pharmacologic resistance to histamine type 2 receptor antagonists (H2RAs) or PPIs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Rapid PPI metabolizers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tolerance to H2RAs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypersecretory states:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gastrinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antral G cell hyperfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic hypersecretory duodenal ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Comorbid conditions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Uremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Catabolic state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary or multisystem failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Co-therapies:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytotoxic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other drugs, such as methamphetamine or cocaine use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Uncommon causes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infections other than",
"        <em>",
"         H. pylori",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eosinophilic and other inflammatory conditions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <em>",
"      H. pylori",
"     </em>",
"     :",
"     <em>",
"      Helicobacter pylori",
"     </em>",
"     ; PPI: proton pump inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5501=[""].join("\n");
var outline_f5_23_5501=null;
var title_f5_23_5502="Abnormal mammograms";
var content_f5_23_5502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Yield of abnormal screening mammograms according to patients' age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 485px; background-image: url(data:image/gif;base64,R0lGODlhrQHlAdUAAP///4CAgAAAAMDAwEBAQP8AADAwMKCgoFBQUHBwcNDQ0CAgIPDw8BAQEGBgYODg4P+AgLCwsP/w8JCQkP+goP+wsP9QUP8QEP8gIP8wMP/g4P/Q0P9wcP9gYP+QkP/AwP9AQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACtAeUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLVUDAcBAUK4AQcMtsHCfAoNAgQLQgbHAgZNAwPD0tNkCwIKQxECCAAIAhFFA7rjAQS71OjpWQoCC9bcAQK78edD4uTl9er7/E4DzQOW5ZIHgB4TXf0SKkTCjkBBeRMEJACQQMCEg/oWakxoLcKyAQ/aDbD2AOPGkwkVLGtwQMgBawtamkRJs+ZMmzhzCkGos2dN/553PnzwSbQRUDsULBRdmuhoHQkFJDCdSshpHQsUqGoFZJVO0q1g+XSdA1Vq2LN2xs7BirbtHLVyOBSYi6GC27tr4MKpMLdvAbt4A5fR+waDX7qCE4sh7OZwX8WQvTBu43hu5MtaJrMxfBgD5s9WNK/hexgw6NNQRI/mXBe16yeq27B9TXtJbDZfa+s+cntN2d3Ah/ReMzv47uFqchvXjTzN7+W1m6cpDt21dDTKq6O+fua59tPcz1D/foqAwz/hzWQnb6oc14x8vLMvVdE8gYl70psZP18UAQEAHiMWfHys159g+pUh34GgMJAAAQogAE5+BPLBH4OdeCPAAA5wQ//hIAZiyIlFBIhznh4JKhiViKB8UyIBHqJYoYVZseiJAw00YI1MMhISoo2XMOBNA/h9OMiCQF7yQDQMDACMkYNcmCQlBnDDwAIODFjIj1NKsuFOJ+aRohlIdilJAxd1E6OYM/YhpZmPONCMQFpuqRSclTAgJ5F9jEnmingy5ed+NQYayQHGABgmHoOWwaWhiRhjX5FsHlImpJFSWqchb2JqSAJZotemH496Ssh/AS56R6MqmmWqIg9Ouimnhb5KE6uO3mkrIhHKCqUhl+4KyDKpzkqrsIcIcIAAADgwahy45oqsIRsuMMCDxhYS7LR7LBCAnNtkW0in3OahgAJCIvD/ZI+KlFruqtw8QMCEYUBjLy+5/NJEtK2+CwhLQjigahcBAqgMM86Eg08+jJDrLx1fFjQwFwDeqw033tArxD3kmMOIuw/LYYABEUTApxiKIhCNQQbZ9iwg24YshzYANlCSGAh8K4DNLBPkciMOywzHAwFMcHMZ/w0Q0UQVpakEv+rpKvQnAencAAMhWUvSTYrEPHUlDxBrADYAvNQOj0+/HEjQX7MCddRt26HAzXOLaymgccvhscR2H8J23mMoQICO5jUwMR1vww34G/8U3IDGjKodiNeLk5EA2n37XWvlaxzwCwKh/vqx1JyrscAE4Dpd6SOUl/7Fhgbcd/hbkgvy/7frXDRAj3uij467GhXBHvrqrOP9exkMTBABAwGQzS4ktx+PhQL2Ok/8IyBLn0XwimaOSOvaW2G4PAtoumrtUW4evhcbCsD8mpFPkv36VLiIQOzef288/VwkEADNmDsfJaLHvyicq0/oAxHpCriOj5wuf/pzFQOzYIAcXWt2ckgccdQ3wSq4yEQQRMT8OrgENM0LSyG8mwRJSIV4BCgavYMeB1kYhQnACHLxq8QIaWgEzykhAeZzgwZ9sz8ePgEBsxMY4hI4rhkacQkvqZ4RJqA7XQRQDUNcg1zoYponLgFV3SsCGAX0hiymgTR+6aIXkZCLcQSQelIsIxMHwRm/eP9mjUtokvWI4CAISQgOZkRDZQqARyUsC0AGWNcQNMQh+OVljoIYZCGToKMAVGR4QiARCOVoiTr25Y6TNEIDYIitInwQRoCEZCDQ2Bc1hhIaDkgALB2JIx0pK5WXqABrXBnKghWrCELaWRCxqEpCQKADoeTNwgK4JAA0SZFsCOQaNFDEZDahSs5EISc1AQInWjMJEeOdEIvpowx8MwpoEgICHEnMTUjgAho45xPkNLJbblMTHeCAPIWwtwQ4Uk/ChBY5CbEBUFqTaAswRwDwF8NO8hKPjSsYfBD1y3F2wgPI/GaTDOAAaOxRCJIyzzDRIM02UHOFoYSjR0U50kd6wgL/HpDnGFUFqiV6ggLmPGcb46E6fhYMg4MZqCEusIF98hOTFLHPfXDpiXyeE44mAypTO7GBC5xzjPDplUin2onWWHOnVyRWGC36CQ8s0KiZXFazhBoatmqrml4M5slMOZILcrUTMLXmfwiwDPh4C1zsTENJ95LTXk6olEQ4V7qg6dJQEDWZunPmOo0QgV0Q7aPtDAUHMjpJ7n3DCN7iZ2ANCBJ8+YKxyhRFVa1pwz8aIZxSXUIxfLaM/yTsZ6LIgDdpqNKPYokBDOAoFoi1i4t147NE4Ng49hYKs4bSs6pyYcWuEAAiEaRnGVGuLpgLCqjEs5A7c+MRDnDDK7CjstdN/++zBiuHvBYytIPxZdEkQhGLcA0UuoQoh0q00jAsiUMCcMADsjYSARwtCeyVw2O96MuxLsZnZovJvtyaiM2ucWG+SKElNGBVPNYNAB8mQj9He4YEy0G3eNybOAGAUIUylKyk2OHxBEe4wYUpogGi8BRMHAfvPhHHO9PYRjs6AMxmthQdgMAaL2fIzyG1saXIrxGdpNIigxZ1AOoplEuBgaHwcEMzfW1AZHfXUViYhwF4wE4zXATdyWPF0dSxIjiM0g5G4MBGCF5AnixYOSsCxUa0bfOOkLzlDfqepqAACJ4YAQdYI1xG6G2ZR/HO7/KQARHYa55/OulRJNmIwUOA0f9E+Z8AlK/ToviAQUm411GL2X0BILEZeFyHLhtRAQlYhiPt9+I20JoOx+Shmh1NRiL4D4CoFsVJaYgqA7j6CAdMtii6ScPTJqGPEcLhkVOB028yskPSDkWlralJOG85FU5N5illHdRWqNqatdxRuEXh1QlqdanAHFJLS+xnRwS7g492sEuu6Ot+N2LZE4Q0EpBoU1cQEHAIaGkU+wtjVnR7gjjylYg5jWhWwHOCYS7CmglOUoM7It2F1GMGTd6I1TJQJdXS8iGbgdo+x6Le9KvgKBE7hEpect6kcG4BP2juUQqB53GOBcLpZ8IIaHNjHJJlI4FOCvfST7oRy2SDY7v/GJY74uL8ay3kMExyfs9iwWgt+Sw4oE/6DQCJW23oKly+vkQJXICzyMBDXTdXBNJC6OEjbxz5OAHxdvwVPg4fuO4e8orHwurSa4bhiQAQihe8FlLWHr6RYACvw8bzkED78TIe953E2ltWpPopziy9xgOgwcW+fC3o3kF72d7IarcFoKWngKLh+egyKbzqTwH43828AdYbMjQYfvhYJP53DVCZR9YE5AAP/xQdiOnxYEuEFutiAjXPvS0yjzsDeCsBfRdCiAU6DAwU9XezpbmIca3UfbdbGKz/nZXp6vqkC4POvwM62pZDwrB7paMh24BD1rZy0qBox6NmmiZGivJs/7InDM/HObi2EvAxbNbAdWHwa4Pwaa6zV7gXAQnwDuZVePriTPkSfkQAgoJAfpVzAEPiADjUarj3BBxXW80wYdOARjgHOBESe0dnDAhwAL8XBS0REsxiXBmjMPjAXePnGHsXMqZWMxUSAd7ggUhwLer1ENm1MFJYC56EGICDDAkwgI32aOzGBORFX9h1X7UgSYCThBtnAAmQg1GQNEtTX1pmBDAICHQYPnemBVUTPAMmEluDW8JQhgWwavsUNgCyABMSYWUnHKA3Caw0F1X4Lk4iCIEICLpEFxfQieWyIUwmKvtQAR/XNtuQUJNHBJV1Wdf3ChxQWFPjWXenZ6BTi/+vkAFt9zUqQWT7RwQN4AAGsEmOhw4cZorlUoz8t1+++AqsaGlCE3+JZAR8tQDe8Ic2lxC32DbuYEnHGGmJko3Nlw7A+DXcdwTQuIzq0IxTw40D4BFI5T/FsAAuOGuZ6AnVKDTH91EsgQA5Yn9kEIqLEI7X6HtHUC05w4VfgJCLsI6lw43ygHTnlhDyyDkRYTOnlo788I8Y+ADPNI21oJAhs35EIHbsRxMUWS4EYIMA8lGeNYDidxIbyS0usgDCZUq7ICQQKRn9OAoiOS0bcozmhlwYuW0ogZLIYn4WoURFsIXL4I036ZLBKCwD0AAG8ADplG8BZZL/V4rTEm1+IJH/kVCUtmIeSnBvBjkGaBkJTvkqHqEEAUeEGVkTL/kq/fd6bWh2PZGTphIrpbdIb8mPRKGWnvJMnzgE5lFBGleBPTGXkHJIAUEpsBeUXRCXlLCXkMKT1mJuaTGUqiCYhgJmdiVG5+BPYpkOioknWNJ5fed9C6WZXMCZlUCZcEIzO3Ng1UeaRYCbleCZeNJ7FOhMe2Z5klkUprmbDKlhJ/GaU8I9yAedJ3GLu9Ql21CP0WedG7GJfzEl1gIm3qkRjgiJB6ILSLRd7MSSrckPgygimblpAWKTgEkV8Ykhtjd4Q0AQQPme+3CeXSJppnRYtrkFwmkJ4OmM34GAeEmV9gWS/z4xio94AbvFHpKXemCZfv6HFh8geiKyedBGN3Z4lWHhARdQZ/2xlZHJT+cgmt/oFh2Aixhid7FHYwllYwB6EhnAWTU6TED2ODu6Ee90odDxIPwJfA2HFxtQAO/HIH05molBAa14ICNXnj4xoypabcApDSDgo+xBmCJKgIIhARigffMRpXWQoKNQVQwaHJSIpUVBpU/aH71GpooBARmwpcARK7omp0thAWdlHGC0AHrYkpchARmgZHHzAIUHfqa1gox4GVVlpK7hlmMARgnDg7eVNqfBinVqHHd5oE2wPFeyIU6IXJ56Gh6AAXz6Ggp3BiQRh8klhl3KDx2waNARcf9p0Ie0ag+26hqKCqa7QXpj+gU/BwB92DRyiBkcZqmYoaZb4A2oBxKKaGDNihlNGqqnKFFlAxOXaHq1QaWvijts2gozOkHn2go9ykDrygrvhKausSEHAENneasaUVVeNq8LRYyHOqRbQaXWCBpjdHdSGhy3WK6BkTywqKHPAxwgAALZ+RkqKXeuQQFU+BlydZjwSBsCGq3H0FeAehf5qRhKSar3FxwlmxiRlS4j6xYfexk1+bJtAZ4gqhjuabGuQaF1gbHQ+i7vGgwfmpV5E7TBoAEZYAEKWy5GGwwSYAEZwK1C07T4dwH7ihfGWaJLyiBU+rNEEZA0CxpVRaxhEX3/9YhNOvsdirqnbtGODysiEtAB7tcW5keOHNuhQIKiXmsT2LiPiJokrMioZ/GO15MkG9CjS3srakYO4QqwryEBIJABA0sUYMZxb9slHXCzPUFltxe2wOGzVJGKwpe2LFJVRKsTyvd2KHuQ+BoYSAsCiZsQ1cdnW2soTxu1PkGbkEq6SQIBVksUFXu5kEKl8ooTmMq7UzK2PSFWeHmwu7K2sZsOysIszuK57JG5UqsR1ZKawvsqemsTfwUgf9mxr/KhgnsSirVOfuu483G4SpsTjSuhrwK5krsRDBM2qwuXrfsaHKC56cCbgxOrePouoJsQpgZgErG+8issytsP7vEP//ZZuw/zutELC1hnsGu6v7oRt7irDhfcvBmcN777psBBtWBBvBhiwmBRUB1QwdahwcYBvf2hwmeBvfNBw2fRteyBw2cxtOTBw2fhvi4cGUB8Frc7uccBw+zRv1dbwkrMHgUcHEXsFsrLsySsBlb8ClPsFmubsXewoJdQjL0gqau6Pu/kGOgZBzErCb1XbJzqg/wzSBAwx3Rcx3Z8x3icx3q8xxCwso6AKueRqhFcEE98IHLMx4icyIpsx37sCP9wHr+6McHKP2tMB5UcCY+8E19Yq1FYyP0Bxl/sxZSQycpKX8w6qeuTxXmgypSgABGRjFhzrVorrmmnEGMUDZYIx/+1HBZbvMuH0Mu+XAjAHMyDMMzEHAjGfMyqqMxTkczMbL3PLAzOHM2FS805Mc3W7LzZfM2evM2ZgM3ezIDhjBPgPM4LbM77UM7ojLfrrBHq3M4xCs8L8c7yjJj1PM/dfM9Gkc/6vAj03M8fyM8AjQj/PNBCadDpLNAIXRUKvdCg2NAO/R4RTQ0FPdHUBdEWDc0ZvQkVvdE7htEePcAhbcEgPdIhbNKz0NEorcsrrcUl3dLsC9ORoNIyjQQ0XdOA+NI4nZc7XQo33dO0DNSo8NNATdQ9bdQ7jdQ4rdQ1zdQy3RU+NARRLdSYYBXLwiNXTdXfrFDjUBFYnaEYFtZiPdb/ZF3WZn3WaJ3War3WbN3Wbv3WcB3Xch3W9ko1+EAnLiERc93W5rHX5cDVe93Xfv3Xg03YhV3Ygn3Yg53YZF3Xo5DVeR2/AX2bOpYglt3QEunUPYQ2U72cF33Qm1nZmA3Rmu13CCraoE3Zpq3ROpEel53ap73ayOsWro3aoQ3b1SzSkQENqt0FvH3bvu3YePDbfEDcXZLZOt3PyK3V9znbzN1W9/rcKevcFk09NzPG4Wfd3Ue4OS0F+xmpqPXdQ7Ak/3obvXAO2I0E550NC9gFTWJ7wJDewLSfT1JZZMwFvbC78g1MubC7AGDfCqwQs3UObwxtxlAPwQXCL5hAvnQw/7bVkAUzBAkuVbExW8jg4D1ojseQDM3SDBnu274UDQWeXCHe4cvQqVsw4TsDDCMu4Tx4NSb+4TpBXP8dLk9oBDR+dBi84FJQMbwtyK+1IcQdPBSeQNbgPEBeBEc+BOzgDHIi2U/w3of0AEku4dAw5U3e4VDuDz2YNFW+MV2+IVn+5D1RXRUxD5v8gtZ1Dv8QD0AVGymzMmnen8egMmDu5izdBOzgDuESySDWDij4D87QMl8gJ1ni50Ng6AAg6GDoBQlufoc+58504ijE6ITOt98Qh/QQUc2T6f5ZPqRcxkdkNUSjXpzeDaR+JbKk4DwOBYIeEMqCXZz+6nRiDVDpZ/9MWBKynmNCkOtCYOvWoGN6YkuJtOsAEgDDbuvAAOw+Q87ytawW8d4gccEBAGQYNBx8aMrRbi8HljTWnq1J0BBgCO3gx+3ibhCOOgHeINxaoOilzDTbDg034+4sNgHqnnVbEBG74A3zBe/lLu/6flyWZe/rrhP/ZeiJqDXYut0AJmDv/cp6qBpVsyexrPB4NvEr/vDNcKix0REfQWCLSAQe/yURIA4yzgWNczMgv/AkzvIlHw8orgXLkowCsfJ4NvOw3hIvf/LXDGHgimDNvuisHtROIIkb7xI/XwRGPzYkXuRSAHMA861nA20rIRP/cYwBvof0JdVJL4GUcvUOkPX/UIB+7XAOuZxnxgBfYC/2oLHc0q2/0f32XRf3cg8Gbl/3EUnaya3PEmnceI/y7P73gj/4hF/4WqDdi2574V5aQgDgwX0viQ/54aD4jd/ehT/gWhcgDHHgAePhMX8FDf56ER7kmh/jn//3Oe7jgU/jY25PWqD6Wif5lCfk0dD6W37Ua651MMLuZk4Qlh70WBDnum/nQb77Qj/owI/359UyObMnS5Jjy+8zzO5Wzd+bqO78p179NgMA01/41L5xTsLt35/uBe8FSQP+0t7tX0L++P73Bx9gS9J5FK/0sAT//23yp08FGH81+w8EDMBwODAEHIKGMDIICAxE6ZRatV6x/1ntltv1fsFh8ZhcNp/BzwDgYRBAFVf1kKB0CNFsN1z/NsSn2vwA6xru8hATFRcZGx0fISMlJykrLS8xMzU3OTs9P0FDRUdJS01PUVNVV1lbXV9hY2VnaWttb3FzdXd5e31/gYOFh4mLjY+Rk5WXmZudn6Gjpaepq62vsbO1t7m7vb+1GQYGwMvNbxPeIs7Z21sX3hyIIggcAtYABhAIEvCmGAIcYBNg3QMH9eLoI0BgwpCACtYoOIhAoDuLFwFEEDChgQAmUALAyygAQToEVhY0ADBBwIEHDY40UIkkQB2BSt48AOngJEaf55IYbAmgzgOiAgAgEHBPZJUnEQyoZMFpr84ABhMQuFkDZYgCAQsSTPD3kyw3Bm8IwItShw7SOvfuWdHpJgGAJ/butWkwgeVWAvMIdIxSlrC2qUwFKEhHUCRLBAMiyGNJTkqdxAC8GmiSwOuCAYsBCPibz0ETmYVRX3ODJ12/OguahnxzEsECKge4DoHq5wFu0UtDjxbEJ3Vxbb0HHIBppUFFKemcG5dOWEFHkoAC9Zwic+x079/Bhxc/nnx58+fRp1e/nn179+/hx5c/n359+/fx59e//30QADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of women without breast cancer for each woman diagnosed with breast cancer among women having an abnormal mammogram when screened for breast cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original source: Carney PA, Miglioretti DL, Yankaskas et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138:168. Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005.&nbsp;Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5502=[""].join("\n");
var outline_f5_23_5502=null;
var title_f5_23_5503="Acute colonic pseudo-obstruction";
var content_f5_23_5503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute colonic pseudo-obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph in a patient with septic shock and leukemia reveals a massively dilated and air filled right and transverse colon. Haustral markings are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Camilleri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_23_5503=[""].join("\n");
var outline_f5_23_5503=null;
